US20230241137A1 - Composition for promoting absorption of phytochemicals - Google Patents
Composition for promoting absorption of phytochemicals Download PDFInfo
- Publication number
- US20230241137A1 US20230241137A1 US18/132,565 US202318132565A US2023241137A1 US 20230241137 A1 US20230241137 A1 US 20230241137A1 US 202318132565 A US202318132565 A US 202318132565A US 2023241137 A1 US2023241137 A1 US 2023241137A1
- Authority
- US
- United States
- Prior art keywords
- group
- carotene
- yogurt
- phytochemical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 148
- 229930000223 plant secondary metabolite Natural products 0.000 title claims abstract description 84
- 235000017807 phytochemicals Nutrition 0.000 title claims abstract description 82
- 238000010521 absorption reaction Methods 0.000 title abstract description 70
- 230000001737 promoting effect Effects 0.000 title abstract description 57
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 128
- 239000004310 lactic acid Substances 0.000 claims abstract description 64
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 64
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 52
- 239000005017 polysaccharide Substances 0.000 claims abstract description 52
- 235000013305 food Nutrition 0.000 claims abstract description 47
- 235000013361 beverage Nutrition 0.000 claims abstract description 45
- 230000001580 bacterial effect Effects 0.000 claims abstract description 31
- 241000186673 Lactobacillus delbrueckii Species 0.000 claims abstract description 24
- 235000013373 food additive Nutrition 0.000 claims abstract description 7
- 239000002778 food additive Substances 0.000 claims abstract description 7
- 150000004676 glycans Chemical class 0.000 claims abstract 4
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 114
- 235000013734 beta-carotene Nutrition 0.000 claims description 114
- 239000011648 beta-carotene Substances 0.000 claims description 114
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 114
- 229960002747 betacarotene Drugs 0.000 claims description 114
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 114
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 68
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 47
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 39
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 31
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 31
- 235000005875 quercetin Nutrition 0.000 claims description 31
- 229960001285 quercetin Drugs 0.000 claims description 31
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 30
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 27
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 claims description 26
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 claims description 21
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 claims description 21
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 claims description 21
- NBZANZVJRKXVBH-ITUXNECMSA-N all-trans-alpha-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CCCC2(C)C)C NBZANZVJRKXVBH-ITUXNECMSA-N 0.000 claims description 21
- 239000011774 beta-cryptoxanthin Substances 0.000 claims description 21
- 235000002360 beta-cryptoxanthin Nutrition 0.000 claims description 21
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 claims description 21
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 claims description 21
- 235000018889 capsanthin Nutrition 0.000 claims description 21
- 235000015140 cultured milk Nutrition 0.000 claims description 21
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 21
- 229960004999 lycopene Drugs 0.000 claims description 21
- 239000001688 paprika extract Substances 0.000 claims description 21
- 235000012658 paprika extract Nutrition 0.000 claims description 21
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 20
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 20
- 235000012661 lycopene Nutrition 0.000 claims description 20
- 239000001751 lycopene Substances 0.000 claims description 20
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 20
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims description 19
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims description 19
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims description 19
- 238000004090 dissolution Methods 0.000 claims description 19
- 229940025878 hesperidin Drugs 0.000 claims description 19
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims description 19
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002994 raw material Substances 0.000 claims description 18
- 239000011795 alpha-carotene Substances 0.000 claims description 13
- 235000003903 alpha-carotene Nutrition 0.000 claims description 13
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 claims description 13
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 10
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 10
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 10
- 235000012734 epicatechin Nutrition 0.000 claims description 10
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 10
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 10
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 10
- 235000007625 naringenin Nutrition 0.000 claims description 10
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 10
- 229940117954 naringenin Drugs 0.000 claims description 10
- 235000006539 genistein Nutrition 0.000 claims description 9
- 229940045109 genistein Drugs 0.000 claims description 9
- 235000012680 lutein Nutrition 0.000 claims description 8
- 229960005375 lutein Drugs 0.000 claims description 8
- 239000001656 lutein Substances 0.000 claims description 8
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims description 8
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims description 8
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims description 8
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims description 8
- 235000009498 luteolin Nutrition 0.000 claims description 7
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 7
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 7
- 235000013824 polyphenols Nutrition 0.000 claims description 7
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 5
- 235000008696 isoflavones Nutrition 0.000 claims description 5
- 150000003505 terpenes Chemical class 0.000 claims description 5
- 229930182497 flavan-3-ol Natural products 0.000 claims description 4
- 229930003949 flavanone Natural products 0.000 claims description 4
- 235000011981 flavanones Nutrition 0.000 claims description 4
- 229930003935 flavonoid Natural products 0.000 claims description 4
- 150000002215 flavonoids Chemical class 0.000 claims description 4
- 235000017173 flavonoids Nutrition 0.000 claims description 4
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims description 4
- 235000011957 flavonols Nutrition 0.000 claims description 4
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 4
- 150000003535 tetraterpenes Chemical class 0.000 claims description 4
- 235000009657 tetraterpenes Nutrition 0.000 claims description 4
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 claims description 3
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 claims description 3
- 150000002208 flavanones Chemical class 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- 150000007946 flavonol Chemical class 0.000 claims description 3
- 150000002898 organic sulfur compounds Chemical class 0.000 claims description 3
- 235000010208 anthocyanin Nutrition 0.000 claims description 2
- 239000004410 anthocyanin Substances 0.000 claims description 2
- 229930002877 anthocyanin Natural products 0.000 claims description 2
- 150000004636 anthocyanins Chemical class 0.000 claims description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims 2
- 150000002212 flavone derivatives Chemical class 0.000 claims 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims 2
- 210000004369 blood Anatomy 0.000 abstract description 38
- 239000008280 blood Substances 0.000 abstract description 38
- 230000005012 migration Effects 0.000 abstract description 11
- 238000013508 migration Methods 0.000 abstract description 11
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 235000013618 yogurt Nutrition 0.000 description 128
- 239000000047 product Substances 0.000 description 79
- 239000000243 solution Substances 0.000 description 65
- 241000700159 Rattus Species 0.000 description 53
- 150000004804 polysaccharides Chemical class 0.000 description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- 238000002474 experimental method Methods 0.000 description 38
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 30
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 30
- 239000001963 growth medium Substances 0.000 description 30
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 29
- 230000037406 food intake Effects 0.000 description 29
- 210000002966 serum Anatomy 0.000 description 29
- 235000021466 carotenoid Nutrition 0.000 description 27
- 125000001409 beta-carotene group Chemical group 0.000 description 26
- 150000001747 carotenoids Chemical class 0.000 description 26
- 235000015190 carrot juice Nutrition 0.000 description 26
- 238000009472 formulation Methods 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 20
- 239000008267 milk Substances 0.000 description 20
- 210000004080 milk Anatomy 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 235000015192 vegetable juice Nutrition 0.000 description 15
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 238000005259 measurement Methods 0.000 description 14
- 235000020384 spinach juice Nutrition 0.000 description 14
- 235000015193 tomato juice Nutrition 0.000 description 14
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 13
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 13
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 13
- 235000005487 catechin Nutrition 0.000 description 13
- 229950001002 cianidanol Drugs 0.000 description 13
- 238000000855 fermentation Methods 0.000 description 13
- 230000004151 fermentation Effects 0.000 description 13
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- 235000008476 powdered milk Nutrition 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000012141 concentrate Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 210000002381 plasma Anatomy 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 241001672694 Citrus reticulata Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 11
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 11
- 235000010209 hesperetin Nutrition 0.000 description 11
- 229960001587 hesperetin Drugs 0.000 description 11
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000008021 deposition Effects 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 235000015205 orange juice Nutrition 0.000 description 10
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 235000008777 kaempferol Nutrition 0.000 description 9
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 125000000763 capsanthin group Chemical group 0.000 description 8
- 238000012258 culturing Methods 0.000 description 8
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 8
- 229930182478 glucoside Natural products 0.000 description 8
- 150000008131 glucosides Chemical class 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002207 metabolite Substances 0.000 description 8
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 8
- 235000005493 rutin Nutrition 0.000 description 8
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 8
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 8
- 229960004555 rutoside Drugs 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 240000007594 Oryza sativa Species 0.000 description 7
- 235000007164 Oryza sativa Nutrition 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 125000000482 beta-cryptoxanthin group Chemical group 0.000 description 7
- 235000009566 rice Nutrition 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 6
- 239000005695 Ammonium acetate Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 6
- 235000019257 ammonium acetate Nutrition 0.000 description 6
- 229940043376 ammonium acetate Drugs 0.000 description 6
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 229940097043 glucuronic acid Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000004885 tandem mass spectrometry Methods 0.000 description 6
- PFPQMWRASYNLMZ-LGIMBNBCSA-N 2-(3,4-dihydroxyphenyl)-3-[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 PFPQMWRASYNLMZ-LGIMBNBCSA-N 0.000 description 5
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 5
- 239000004212 Cryptoxanthin Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 5
- 102000007544 Whey Proteins Human genes 0.000 description 5
- 108010046377 Whey Proteins Proteins 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000008800 isorhamnetin Nutrition 0.000 description 5
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 5
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 5
- 229930019673 naringin Natural products 0.000 description 5
- 229940052490 naringin Drugs 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229920001277 pectin Polymers 0.000 description 5
- 239000001814 pectin Substances 0.000 description 5
- 235000010987 pectin Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 244000000626 Daucus carota Species 0.000 description 4
- 235000002767 Daucus carota Nutrition 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 244000299461 Theobroma cacao Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000014048 cultured milk product Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000011194 food seasoning agent Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007974 sodium acetate buffer Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 229910021642 ultra pure water Inorganic materials 0.000 description 4
- 239000012498 ultrapure water Substances 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108010004103 Chylomicrons Proteins 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- XFZJEEAOWLFHDH-NFJBMHMQSA-N Epicatechin-(4beta->8)-catechin Natural products C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 3
- 244000046052 Phaseolus vulgaris Species 0.000 description 3
- 241000219315 Spinacia Species 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- -1 cysteine sulfoxides Chemical class 0.000 description 3
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000021119 whey protein Nutrition 0.000 description 3
- 235000008939 whole milk Nutrition 0.000 description 3
- XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 2
- 244000291564 Allium cepa Species 0.000 description 2
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 2
- 244000099147 Ananas comosus Species 0.000 description 2
- 235000007119 Ananas comosus Nutrition 0.000 description 2
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 2
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 2
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- 244000089742 Citrus aurantifolia Species 0.000 description 2
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 101100422415 Dictyostelium discoideum ssrp1 gene Proteins 0.000 description 2
- 102000008192 Lactoglobulins Human genes 0.000 description 2
- 108010060630 Lactoglobulins Proteins 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 101150084576 Ssrp gene Proteins 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- 244000185386 Thladiantha grosvenorii Species 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 2
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 2
- 235000008714 apigenin Nutrition 0.000 description 2
- 229940117893 apigenin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000013793 astaxanthin Nutrition 0.000 description 2
- 239000001168 astaxanthin Substances 0.000 description 2
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 2
- 229940022405 astaxanthin Drugs 0.000 description 2
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 235000015155 buttermilk Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000005594 diketone group Chemical group 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 235000015927 pasta Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 150000003243 quercetin Chemical class 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000013076 target substance Substances 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- HYGKYXGLJBDJOX-UHFFFAOYSA-N 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one;2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1.C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 HYGKYXGLJBDJOX-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- MQVRGDZCYDEQML-UHFFFAOYSA-N Astragalin Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(CO)O2)O)C(=O)C2=C(O)C=C(O)C=C2O1 MQVRGDZCYDEQML-UHFFFAOYSA-N 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-UHFFFAOYSA-N Beta psi-carotene Chemical compound CC(C)=CCCC(C)=CC=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C HRQKOYFGHJYEFS-UHFFFAOYSA-N 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000007871 Chrysanthemum coronarium Nutrition 0.000 description 1
- 244000067456 Chrysanthemum coronarium Species 0.000 description 1
- 235000009088 Citrus pyriformis Nutrition 0.000 description 1
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- VMBCEJXTYHMTMM-UHFFFAOYSA-N F.F.I Chemical compound F.F.I VMBCEJXTYHMTMM-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000016816 Pisum sativum subsp sativum Nutrition 0.000 description 1
- 229920000385 Procyanidin B1 Polymers 0.000 description 1
- 229920002350 Procyanidin B2 Polymers 0.000 description 1
- GMISZFQPFDAPGI-HZZPXJBDSA-N Procyanidin B5 Natural products C1([C@@H]2[C@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=C3C[C@H]([C@H](OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 GMISZFQPFDAPGI-HZZPXJBDSA-N 0.000 description 1
- 229920001263 Procyanidin B5 Polymers 0.000 description 1
- MOJZMWJRUKIQGL-FQVWZTFVSA-N Procyanidin C1 Natural products O[C@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@@H]3[C@@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@H]1c1c(O)cc(O)c2c1O[C@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FQVWZTFVSA-N 0.000 description 1
- 229920001554 Procyanidin C1 Polymers 0.000 description 1
- MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 244000150738 Sesamum radiatum Species 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 235000011453 Vigna umbellata Nutrition 0.000 description 1
- 240000001417 Vigna umbellata Species 0.000 description 1
- 240000003584 Ziziphus jujuba Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001895 carotenoid group Chemical group 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 108010067454 caseinomacropeptide Proteins 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 235000020186 condensed milk Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- VZFRNCSOCOPNDB-UHFFFAOYSA-N domoic acid Natural products OC(=O)C(C)C=CC=C(C)C1CNC(C(O)=O)C1CC(O)=O VZFRNCSOCOPNDB-UHFFFAOYSA-N 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940030275 epigallocatechin gallate Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000011663 gamma-carotene Substances 0.000 description 1
- 235000000633 gamma-carotene Nutrition 0.000 description 1
- HRQKOYFGHJYEFS-RZWPOVEWSA-N gamma-carotene Natural products C(=C\C=C\C(=C/C=C/C=C(\C=C\C=C(/C=C/C=1C(C)(C)CCCC=1C)\C)/C)\C)(\C=C\C=C(/CC/C=C(\C)/C)\C)/C HRQKOYFGHJYEFS-RZWPOVEWSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- JPUKWEQWGBDDQB-QSOFNFLRSA-N kaempferol 3-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-QSOFNFLRSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 235000020191 long-life milk Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229960001913 mecysteine Drugs 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 235000020245 plant milk Nutrition 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- GMISZFQPFDAPGI-UHFFFAOYSA-N proanthocyanidin B5 Natural products OC=1C=C2OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 GMISZFQPFDAPGI-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- XFZJEEAOWLFHDH-UKWJTHFESA-N procyanidin B1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UKWJTHFESA-N 0.000 description 1
- GMISZFQPFDAPGI-CVJZBMGUSA-N procyanidin B5 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=C3C[C@H]([C@H](OC3=CC=2O)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 GMISZFQPFDAPGI-CVJZBMGUSA-N 0.000 description 1
- MOJZMWJRUKIQGL-XILRTYJMSA-N procyanidin C1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C2=C3O[C@@H]([C@H](O)[C@H](C3=C(O)C=C2O)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)C=2C=C(O)C(O)=CC=2)=CC=C(O)C(O)=C1 MOJZMWJRUKIQGL-XILRTYJMSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 235000015487 sulforaphane Nutrition 0.000 description 1
- 229960005559 sulforaphane Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000015113 tomato pastes and purées Nutrition 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A23Y2220/15—
-
- A23Y2240/75—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Definitions
- the present invention relates to a composition for promoting absorption of a phytochemical, having an action of promoting absorption of a poorly water-soluble phytochemical into a body.
- Phytochemicals generally mean compounds that are originated from a plant and not essential to keep a usual body function but have a favorable effect on a health condition.
- isoflavone which is a polyphenol
- quercetin is much included in an onion and has functions of improving a blood flow and reducing a body fat
- ⁇ -carotene which is a terpenoid, is much included in a carrot and a pumpkin, and has functions of maintaining a visual function, an internal mucosa membrane and a skin, and an immune function
- lycopene is much included in a tomato and has functions of decreasing a blood cholesterol and a blood pressure.
- phytochemicals are decomposed by being processed and cooked, and eventually disappears, and also known that their migration into a body is sluggish due to many poorly water-soluble components contained therein.
- Illustrative examples of the popular method for promoting absorption of the poorly water-soluble phytochemical include a method of improving solubility and dispersibility of the phytochemical by its emulsification and formulation, a method of making a particle diameter of the phytochemical smaller, and a method of amorphizing the phytochemical.
- JP 2016-216440 A discloses, as catechins-absorbing promotor, at least one selected from the group consisting of resveratrol, hesperetin, extract from a luo han guo (Siraitia grosvenorii), extract from a red date ( Zizyphus jujuba var.
- inermis extract from a lime ( Citrus aurantiifolia ), extract from a lemon ( Citrus limon ), extract from a pineapple ( Ananas comosus ), apigenin, glucose, difructose dianhydride III, sucralose, aspartame or a salt thereof, erythritol, inositol, citric acid or a salt thereof, phytic acid or a salt thereof, and gallic acid or a salt thereof.
- JP 2016-93143 A discloses that when a polyphenol such as catechin having low bioavailability is added to a prescribed blend of a fat and a hydrocarbon, absorption of the polyphenol such as catechin as well as accumulation thereof in a blood plasma can be enhanced.
- JP 2016-506381 A discloses an enhancer of the bioavailability of catechin, containing cyclodextrin as an active ingredient.
- a lactic acid bacterial product which contains a polysaccharide as an active ingredient, has an action of promoting absorption of a phytochemical.
- JP H08-322464 A discloses fermented milk obtained by adding about 0.1 to about 2,000 ppm of catechin and tocopherol, respectively, to yogurt containing a lactic acid bacterium and a Bifidobacterium , thereby increasing a productivity of the Bifidobacterium .
- JP 2015-527076 A discloses a method for producing a nutrient composition based on a richly-textured milk product, containing a phytochemical.
- a lactic acid bacterial product has an action of promoting absorption of a phytochemical.
- a part of the inventors of the present invention previously found that a polysaccharide-containing lactic acid bacterial product significantly improved the intake of a poorly water-soluble phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood; and thus, suggested providing a composition having an action of promoting absorption of the poorly water-soluble phytochemical into a body (PCT/JP2018/010366).
- a polysaccharide-containing lactic acid bacterial product produced by a particular strain is capable of significantly promoting the intake of a poorly water-soluble phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood.
- the present invention has an object to provide a composition for promoting absorption of a phytochemical, which has an action of promoting absorption of a poorly water-soluble phytochemical into a body.
- the present invention has an object to provide a food additive comprising the composition for promoting absorption of a poorly water-soluble phytochemical, as well as a food, a beverage, or a food or beverage composition to which said composition or said food additive is added.
- composition for promoting absorption of a poorly water-soluble phytochemical comprises a polysaccharide-containing lactic acid bacterial product as an active ingredient, wherein the lactic acid bacterial product is a product produced by Lactobacillus delbrueckii ssp. bulgaricus OLL1251.
- the food additive, the food or a beverage, or the food or beverage composition according to the present invention comprises the composition for promoting absorption of a poorly water-soluble phytochemical according to the present invention.
- the present invention relates to a method for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal, comprising the step of administering or ingesting a polysaccharide-containing lactic acid bacterial product to the human or the animal.
- the present invention relates to a use of a polysaccharide-containing lactic acid bacterial product, for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal.
- the present invention relates to a use of a polysaccharide-containing lactic acid bacterial product, for preparing the composition for promoting absorption of a poorly water-soluble phytochemical.
- FIG. 1 A graph illustrating a change of a p-cryptoxanthin concentration in a serum when p-cryptoxanthin alone is administered, or p-cryptoxanthin and a yogurt are administered simultaneously, to a rat.
- FIG. 2 A graph illustrating a change of a p-cryptoxanthin concentration in a serum when capsanthin alone is administered, or capsanthin and a yogurt are administered simultaneously, to a rat.
- FIG. 3 A graph illustrating a change of a hesperetin conjugate concentration in a serum when hesperidin alone is administered, or hesperidin and a yogurt are administered simultaneously, to a rat.
- a “phytochemical” means a natural chemical compound present in a plant, a modified body thereof, and a composition containing the compound or the body, wherein the compound, the body, or the composition is administered or is going to be administered as a substance which has a favorable effect on the maintenance or improvement of a health condition but which is not essential to maintain a usual body function.
- the phytochemical means not only a pure or a somewhat pure compound that is originated from a plant but also a plant-originated composition containing the compound as a main component, or the like, e.g., a fraction of the composition.
- the phytochemical means for example, a polyphenol, an organic sulfur compound, and a terpenoid.
- illustrative examples of the preferred polyphenol include flavonoids, diketones and tetraterpene.
- flavonoids include flavones (for example, apigenin and luteolin), isoflavones (for example, genistein and daidzein), flavonols (for example, quercetin, myricetin, and kaempferol), flavanones (for example, hesperetin and naringenin), flavan-3-ols (for example, catechin and epicatechin), and anthocyanins (for example, cyanidin and delphinidin).
- Curcumin may be mentioned as a specific example of the diketones.
- Illustrative examples of the preferred organic sulfur compound include isothiocyanates (for example, sulforaphane), cysteine sulfoxides (for example, methylcysteine sulfoxide), and sulfines (for example, allicin).
- Tetraterpene may be mentioned as the terpenoid.
- illustrative examples thereof include carotenoids (for example, ⁇ -carotene, ⁇ -carotene, ⁇ -cryptoxanthin, lycopene, lutein, capsanthin, and astaxanthin).
- phytochemicals include analogues of the compounds mentioned above.
- Illustrative examples of the preferred analogues include: in the case of genistein, its glucoside (genistin) and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of quercetin, its methylated body (isorhamnetin), glucosides (rutin and quercetin glucoside), and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of kaempferol, its glucoside (hesperidin) and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of epicatechin and catechin, their isomers (catechin), polymers (procyanidin B1, procyanidin B2, procyanidin B5, procyanidin C1, and so forth), conjugates (glucuronic acid conjugate and sulfuric acid conjugate), and gallic acid esters (epicatechin gallate and epigallocatechin gallate); in the case
- phytochemicals include extracted and concentrated products that are originated from a plant.
- Preferred examples thereof include: in the case of genistein, extracted and concentrated products originated from a soy bean, a red bean, a green pea, and a broad bean; in the case of quercetin, extracted and concentrated products originated from an onion and an apple; in the case of kaempferol, extracted and concentrated products originated from a tea and a broccoli; in the case of epicatechin and catechin, extracted and concentrated products originated from a cacao bean and a tea; in the case of hesperetin, extracted and concentrated products originated from a mandarin orange; in the case of naringenin, extracted and concentrated products originated from a grapefruit and an orange; in the case of luteolin, extracted and concentrated products originated from a wild sesame, a perilla, a crown daisy, and a green pepper; in the case of epicatechin, extracted and concentrated products originated from a cacao bean; in the case of ⁇ -car
- the phytochemical is poorly water-soluble.
- a poorly water-soluble phytochemical is the one having the dissolution rate in water of 88% or less, preferably 50% or less, more preferably 20% or less, the most preferably 1% or less.
- the “dissolution rate” is an index indicating dissolvability of a compound into water, and is also represented by the value, in terms of the percentage (%), obtained by dividing a concentration (w/v) of the compound in a supernatant, which is obtained by shaking the compound in pure water to dissolve the compound therein and by centrifuging the solution, by a concentration (w/v) of the compound in pure water before being dissolved therein.
- the concentration may be measured by using a spectrophotometer.
- a solution prepared by adding 33.3 mg of a phytochemical compound into 10 mL of pure water is used for the measurement of the “dissolution rate”.
- the “dissolution rate” may be measured by using a solution that is prepared by adding 3.3 mg of a phytochemical compound into 10 mL of pure water.
- the temperature condition in the measurement of the “dissolution rate” is set to 21 ⁇ 2° C.
- poor water solubility of the phytochemical may be expressed, as an index, by “a concentration (w/v) of the compound in a supernatant, which is obtained by shaking the compound in pure water to dissolve the compound therein and by centrifuging the solution”; in this case, the dissolution rate of 88% or less corresponds to 293 mg/100 g or less.
- the phytochemical to be promotingly absorbed is not necessarily in a condition of being dissolved in water. Namely, it is considered that the effect of promoting absorption of the phytochemical exhibited by the present invention can be also obtained when the phytochemical is ingested in a solid condition or in a condition of being suspended in water.
- composition for Promoting Absorption Composition for Promoting Absorption
- promoting absorption of a phytochemical means that the intake of the phytochemical into a body, in particular, a migration speed and/or a migration amount of the phytochemical into a blood is significantly increased, in comparison with a reference in which the phytochemical is ingested without a polysaccharide-containing lactic acid bacterial product.
- promoting absorption of a phytochemical means that, after the composition is administered, a higher blood concentration is obtained in comparison with the reference, and/or, a larger Area Under the blood concentration-time Curve (AUC) is obtained in comparison with the reference. This allows not only obtaining an effect of ingesting the phytochemical with a smaller quantity or a shorter time, but also reducing costs for a raw material(s).
- adding the composition for promoting absorption of phytochemical according to the present invention to a food, or a beverage, or a food or beverage composition can enhance an added value of the food or beverage or the like, and thereby also can enhance a commercial value of the same.
- a polysaccharide-containing “lactic acid bacterial product” widely means not only a product fermented with a lactic acid bacterium, but also a composition that is supposed to contain a polysaccharide, as a result of fermentation using a lactic acid bacterium, such as a cultured product with a lactic acid bacterium and a lactic acid bacterial metabolite.
- polysaccharide is a saccharide-chained polymer formed of saccharides such as galactose, glucose, rhamnose, mannose, and N-acetyl glucosamine.
- the polysaccharide may include a neutral polysaccharide and/or an acidic polysaccharide bound to a phosphoric acid group. The molecular weight thereof is usually in the range of 5,000 to 500,000.
- Lactobacillus delbrueckii ssp. bulgaricus OLL1251 (which may be hereinafter abbreviated as “ Lactobacillus bulgaricus OLL1251”, or “OLL1251”) is used, as the “lactic acid bacterial product”.
- the “lactic acid bacterial product” produced by OLL1251 has a superior action of promoting absorption of phytochemical in comparison to a product produced by analogous strains.
- the “lactic acid bacterial product” produced by a combination of OLL1251 and Streptococcus thermophilus OLS3290 (which may be hereinafter abbreviated as “OLS3290”).
- OLL1251 and OLS3290 can obtain merits of efficiently producing the “lactic acid bacterial product”, in particular, of obtaining the “lactic acid bacterial product” having a superior action of promoting absorption of the phytochemical in a short fermentation time.
- Lactobacillus delbrueckii ssp. bulgaricus OLL1251 described above is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan) with the deposition date of 25 Apr. 2018 and as the deposition number of NITE BP-02703.
- Streptococcus thermophilus OLS3290 is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center with the deposition date of 19 Jan. 2004 and as the deposition number of FERM BP-19638.
- the “product fermented with a lactic acid bacterium” means: a cultured product obtained by fermentation with the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or, as the preferred aspect, with a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290; and a composition including the cultured product; and a composition obtained by processing the composition.
- the product fermented with a lactic acid bacterium includes a product fermented with Lactobacillus delbrueckii ssp.
- bulgaricus OLL1251 or with a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290, as well as a product obtained by processing said fermented product.
- Illustrative examples of the processed product include: a filtrated solution or a supernatant solution of the cultured product that are obtained by sterilizing the cultured product (the product fermented with a lactic acid bacterium) using, for example, filtration, centrifugation, or membrane separation; a concentrated product obtained, using an evaporator or the like, from said filtrated solution or supernatant solution, or product fermented with a lactic acid bacterium, or the like; a pasted product of the fermented product; a diluted product of the fermented product; and a dried product of the fermented product (obtained by, for example, freeze-drying, heat-drying, or decompression-drying).
- the processing may be carried out by any one of or a combination of a plurality of said processes such as treatments of sterilization (for example, filtration, centrifugation, and membrane separation), precipitation, concentration, pasting, dilution, and drying.
- sterilization for example, filtration, centrifugation, and membrane separation
- precipitation precipitation
- concentration pasting
- dilution drying
- drying illustrative examples of culture media include a defatted milk powder culture medium to which a yeast extract is added and an MRS culture medium.
- the lactic acid bacterial product is especially preferably a fermented milk product, a cultured milk product, or a milk metabolite, which is produced by the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or by a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290.
- Fermented milk (yogurt) may be mentioned as an example of the fermented milk product, the cultured milk product, or the milk metabolite.
- the fermented milk (yogurt) may be preferably a supernatant thereof.
- a defatted powder milk and a culture solution such as a decomposed product of whey, as well as a thickener or a gelling agent, such as pectin, guar gum, xanthan gum, carrageenan, processed starch may be added.
- illustrative examples of milk include animal milk such as cow milk and a processed product thereof (for example, defatted milk, whole milk powder, defatted milk powder, condensed milk, casein, whey, fresh cream, compound cream, butter, butter milk powder, and cheese), and plant milk such as soybean milk originated from soybeans.
- the milk may be sterilized or not be sterilized.
- a so-called raw material admixture for fermented milk may be used as the raw material for fermented milk (yogurt).
- the raw material admixture for fermented milk is a mixture containing raw material milk and other ingredients.
- the raw material admixture for fermented milk may be obtained by dissolving, on heating, raw materials that are normally used to produce the fermented milk, such as, raw material milk, water, and other optional ingredients (for example, sugar, carbohydrate, sweetener, acidulant, mineral, vitamin, and fragrance), and thereafter by mixing the raw materials thus dissolved.
- the raw material milk may include water, raw milk, sterilized milk, defatted milk, powdered whole milk, powdered defatted milk, concentrated whole milk, concentrated defatted milk, butter milk, butter, cream, cheese, and the like.
- the raw material milk may include whey protein concentrate (WPC), whey protein isolate (WPI), ⁇ -lactoalbumin ( ⁇ -La), ⁇ -lactoglobulin ( ⁇ -Lg), and the like.
- fermented milk may be prepared by the conventional methods in the art.
- fermented milk may be prepared via steps: such as a preparation step of a raw material admixture, a (heat-)sterilization step of the raw material admixture, a cooling step of the raw material admixture, an adding step of a starter, a fermentation step, and a cooling step of fermented milk.
- steps: such as a preparation step of a raw material admixture, a (heat-)sterilization step of the raw material admixture, a cooling step of the raw material admixture, an adding step of a starter, a fermentation step, and a cooling step of fermented milk may be prepared via steps: such as a preparation step of a raw material admixture, a (heat-)sterilization step of the raw material admixture, a cooling step of the raw material admixture, an adding step of a starter, a fermentation step, and a cooling step of fermented milk
- a culture medium usually used for culturing a lactic acid bacterium in the art may be used, as a culture medium for culturing the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290.
- any culture medium may be used so far as the culture medium properly contains a main carbon source as well as a nitrogen source, an inorganic substance and other nutrients.
- lactose glucose, sucrose, fructose, starch hydrolysate, molasses and the like may be used in accordance with assimilation of a strain to be used.
- nitrogen source nitrogen-containing organic substances such as casein hydrolysate, whey protein hydrolysate, ⁇ -lactoalbumin, ⁇ -lactoglobulin, glycomacropeptide, and soybean protein hydrolysate.
- meat extract, fish extract, yeast extract, or the like may be used, as a growth promoter.
- the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 anf Streptococcus thermophilus OLS3290 may be cultured under an anaerobic condition, or under a slightly aerobic condition that is used in liquid static culturing and the like.
- a known culturing method such as one under a carbon gas phase may be used, or another method may be used, too.
- the culturing temperature is preferably in the range of 30° C. or more to 47° C.
- the pH of the culture medium during culturing of the lactic acid bacterium is kept preferably in the range of 6 or more to 7 or less; but may be in another range so far as the bacterium can be grown.
- the culturing time of the lactic acid bacterium and the like is preferably in the range of 1 hour or more to 48 hours or less, more preferably in the range of 1.5 hours or more to 36 hours or less, still more preferably in the range of 2 hours or more to 24 hours or less.
- fermented milk typically has a milk solids-not-fat concentration of 8% by weight or more, and also has the number of lactic acid bacterium or the number of yeast in the range of 10 6 /mL or more to 10 11 /mL or less.
- the “lactic acid bacterial product” may be used as it is in the form of a fermented product, a cultured product, a metabolite, or the like, which is produced by the lactic acid bacterium, Lactobacillus deibrueckii ssp. bulgaricus OLL1251, or a combination of Lactobacillus deibrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290. It is preferable that the composition for promoting absorption is used in its pharmaceutically formulated form.
- the “composition for promoting absorption” includes, for example, not only a pharmaceutical but also those supplied in a form as they are, or preferably those supplied in a form of formulation orally ingested, i.e., in a form of a so-called supplement. Also, the composition for promoting absorption includes those added, as food additives, to other food, or other food or beverage, thereby providing the food, or the food or beverage with an action of promoting absorption of phytochemical.
- a food or a beverage comprising the composition for promoting absorption of phytochemical according to the present invention; the food or the beverage processed; and the food or beverage composition are also encompassed in the present invention.
- a formulation is prepared by a usual method concurrently using an additive acceptable for formularization.
- the formulation is preferably prepared as an oral formulation.
- the formulation may be in a form of a solid formulation such as a tablet, a powder, a fine granule, a granule, a capsule, a pill, and a sustained release agent; or in the form of liquid formulation such as a solution, a suspension, and an emulsion.
- Illustrative examples of the additive acceptable for formularization include an excipient, a stabilizer, a preservative, a wetting agent, an emulsifier, a lubricating agent, a sweetener, a colorant, a fragrance, a buffering agent, an antioxidant, and a pH-adjusting agent.
- illustrative examples of the food additive include seasonings such as a processed seasoning, a flavor seasoning, and a seasoning admixture.
- a food, or a beverage, and a food or beverage composition may be those processed so that a human or an animal can eat or drink them, and may be in orally ingestible form such as a solution, a suspension, an emulsion, a powder, or a molded solid agent, but are not limited to the above.
- illustrated examples of the food or the beverage, and the food or beverage composition include milk products such as a milk beverage (including processed milk), a yogurt, a lactic acid bacterium beverage, a fermented milk, an ice cream, a cream, and a cheese; beverages such as a refreshing beverage, a fruit drink, a vegetable drink, a soybean drink, a coffee drink, a tea drink, a jelly drink, an energy drink, a beauty drink, cocoa, a powdered drink such as smoothie, a powdered sports drink, a nutrient-reinforcing powdered drink, a powdered beauty food, a powdered soup, a source of steamed bread, a concentrated drink, and an alcoholic drink; wheat products such as a bread, a pasta, a noodle, a cake admixture, a frying powder, and a bread powder; sweets such as a chocolate, a gum, a candy, a cookie, a gummi, a snack,
- beverages
- the food, or a beverage, and the food or beverage composition also include those classified as a functional food, a health and nutrition food, a health food, a food for specified health use, a food with functional claims, a nutrition functional food, a patient food, a formulated milk powder for a baby, a powdered milk for a pregnant or for a lactating mother, a food or beverage with a note of a reduced disease risk, and the like.
- the note of a reduced disease risk is a note which indicates that the food or a beverage is capable of reducing a disease risk, and also is determined or recognized on the basis of or with reference to the criteria determined by the FAO-WHO Codex Alimentarius Committee (Codex Committee).
- an optional ingredient may be added, as needed.
- the optional ingredient includes those usually blended in a food or a beverage: for example, a sweetener; an acidulant; a juice or an extract of a vegetable, a fruit and a seed; nutritional elements such as a vitamin, a mineral, and an amino acid; a lactic acid bacteria (except for the essential lactic acid bacterium according to the embodiment of the present invention), useful microorganisms such as a Bifidobacterium and a propionic acid bacterium, and their fermented products; functional carbohydrates such as an oligosaccharide; existing functional stuff such as royal jerry, glucosamine, astaxanthin, collagen, and polyphenol; and a flagrance, a pH adjusting agent, an excipient, an acidulant, a colorant, an emulsifier, and a preservative.
- the polysaccharide-containing lactic acid bacterial product for producing the composition for promoting absorption of a poorly water-soluble phytochemical according to the present invention.
- the ingesting amount of the composition for promoting absorption of phytochemical may be determined as appropriate.
- the ingesting amount of the composition corresponds to the ingesting amount of the polysaccharide in the range of about 200 ⁇ g or more/day, preferably in the range of 200 ⁇ g/day or more to 60,000 ⁇ g/day or less, more preferably in the range of 300 ⁇ g/day or more to 45,000 ⁇ g/day or less, still more preferably in the range of 400 ⁇ g/day or more to 30,000 ⁇ g/day or less, the most preferably in the range of 500 ⁇ g/day or more to 15,000 ⁇ g/day or less.
- the ingesting time is not particularly limited.
- the composition is orally ingested at least one time or more.
- a necessary administering amount obtained from animal testing may be converted to a necessary administering amount for a human body by using the following formula based on the written material of the Food Safety Commission.
- a method for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal comprising the steps of administering or ingesting a polysaccharide-containing lactic acid bacterial product to the human or the animal.
- a polysaccharide-containing lactic acid bacterial product for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal.
- the precipitate was centrifuged under the condition: at 10,000 rpm for 10 minutes at 4° C., and thereafter, 3 mL of ultrapure water was added to the precipitate thus obtained to prepare a polysaccharide extract solution. Then, 500 ⁇ L of a phenol reagent (5% (w/v)) was added to 500 ⁇ L of the polysaccharide extract solution, and then, the resulting mixture solution was stirred. Immediately after 2.5 mL of concentrated sulfuric acid was added to the mixture solution, and the resulting mixture solution was stirred for 10 seconds. Then, the mixture solution was statically left for 20 minutes or more at room temperature, the absorbance of the mixture solution at 490 nm was measured with a spectrophotometer.
- the reference solution was prepared as described below, and the absorbance thereof at 490 nm was measured in a similar manner to the above.
- 500 ⁇ L of the phenol reagent (5% (w/v)) was added to 500 ⁇ L of a standard glucose solution, followed by stirring the resulting mixture solution.
- a standard glucose solution 500 ⁇ L
- concentrated sulfuric acid was added to the mixture solution, and the resulting mixture solution was stirred for 10 seconds. Then, the mixture solution was left statically for 20 minutes or more at room temperature.
- a glucoronidase solution 10,000 U/mL; manufactured by Sigma-Aldrich Corp.
- the column was kept with 30% of the B solution for 1 minute, and then, the concentration gradient of B solution was gradually changed up to 45% during a period of 4.5 minutes to elute a target substance. Then, the column was washed with 99% B solution for 2 minutes, and was kept with 30% B solution for 3 minutes. The flow rate was set to 0.3 mL/minute.
- the MS/MS analysis was carried out with an ESI negative mode. The MS/MS analysis was carried out under the following condition: a curtain gas flow rate of 30 psi; a collision gas flow rate of 9 psi; an ion spray voltage of ⁇ 4500 V; a turbo gas temperature of 600° C., and an ion source gas of 70 psi.
- the 1200 series (manufacture by Agilent Technologies, Inc.) was used.
- TSKgel ODS-80 TsQA (5.0 ⁇ 250 mm) (manufactured by Tosoh Corp.) was used as a column.
- Column temperature was set at 40° C.
- the flow rate was set to 0.3 mL/minute, and the absorbance at the wavelength of 450 nm was measured.
- Epicatechin (manufactured by Sigma-Aldrich Corp.), catechin (manufactured by Tokyo Chemical Industry Co., Ltd.), quercetin (manufactured by Wako Pure Chemical Industries, Ltd.), genistein (manufactured by Tokyo Chemical Industry Co., Ltd.), rutin (manufactured by Wako Pure Chemical Industries, Ltd.), ⁇ -glucosyl rutin (manufactured by Wako Pure Chemical Industries, Ltd.), hesperidin (manufactured by Wako Pure Chemical Industries, Ltd.), naringin (manufactured by Sigma-Aldrich Corp.), naringenin (manufactured by Sigma-Aldrich Corp.), kaempferol (manufactured by Extra Synthase Inc.), ⁇ -carotene (manufactured by Wako Pure Chemical Industries, Ltd.), ⁇ -cryptoxanthin (manufactured by Wako Pure
- aglycone portion other than carbohydrate obtained by hydrolysis of glucoside
- the amount of aglycone can be equal to 33.3 mg; namely, 67.3 mg of rutin (33.3 mg of quercetin); 89.6 mg of ⁇ -glucosyl rutin (33.3 mg of quercetin); 67.3 mg of hesperidin (33.3 mg of hesperetin); or 71.0 mg of naringin (33.3 mg of naringenin).
- terpenoids in accordance with the administering amount used in Experiments, 10 mL of ultrapure water was added to 3.3 mg of each of ⁇ -carotene and lycopene. The solutions thus prepared were shaken for 3 hours, and then, were centrifuged at 2000 ⁇ g for 10 minutes. The centrifuged supernatants were filtrated by using a 0.45 ⁇ L filter.
- the absorbance of the centrifuged supernatants were measured by using a spectrophotometer (at 280 nm in the cases of epicatechin, catechin, hesperidin, naringin, naringenin, and luteolin; at 260 nm in the case of genistein; at 360 nm in the cases of quercetin, rutin, ⁇ -glucosyl rutin, and kaempferol; at 450 nm in the cases of ⁇ -carotene, ⁇ -carotene, and ⁇ -cryptoxanthin; and at 470 nm in the cases of lycopene and capsanthin).
- a spectrophotometer at 280 nm in the cases of epicatechin, catechin, hesperidin, naringin, naringenin, and luteolin; at 260 nm in the case of genistein; at 360 nm in the cases of quercetin,
- Dissolution rate (%) [(concentration of the centrifuged supernatant after dissolution by shaking (w/v)) ⁇ (concentration of the solution before dissolution by shaking (w/v)] ⁇ 100
- Catechin and ⁇ -glucosyl rutin had the dissolution rate of 89% or more; and thus, they were water-soluble phytochemicals.
- epicatechin, genistein, quercetin, rutin, kaempferol, hesperidin, naringin, naringenin, ⁇ -carotene, ⁇ -carotene, lycopene, luteolin, ⁇ -cryptoxanthin, and capsanthin had the dissolution rate of 88% or less; and thus, they were poorly water-soluble.
- Lactobacillus delbrueckii ssp. bulgaricus OLL1251 , Lactobacillus deibrueckii ssp. bulgaricus OLL1224, and Lactobacillus delbrueckii ssp. bulgaricus OLL1247 each were applied to a culture medium containing 10% by mass of defatted powdered milk and 0.5 mM of sodium formate, and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.6.
- the yogurts thus obtained contained 136 ⁇ g/g, 88 ⁇ g/g, and 68 ⁇ g/g of the polysaccharide, respectively.
- Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums.
- the ⁇ -carotene concentrations in the respective serums were measured in accordance with the method described above.
- the rat group to which ⁇ -carotene was administered is called “ ⁇ -carotene group”; the rat group to which the mixture of ⁇ -carotene and the yogurt ( Lactobacillus bulgaricus OLL1251) was administered (Example) is called “ ⁇ -carotene+OLL1251 group”; the rat group to which the mixture of ⁇ -carotene and the yogurt ( Lactobacillus bulgaricus OLL1224) was administered (Comparative Example) is called “ ⁇ -carotene+OLL1224 group”; and the rat group to which the mixture of ⁇ -carotene and the yogurt ( Lactobacillus bulgaricus OLL1247) was administered (Comparative Example) is called “ ⁇ -carotene+OLL1247 group.”
- Results are shown in Table 2.
- the area under the blood concentration-time curve (AUC) was significantly increased in all of the ⁇ -carotene+OLL1251 group, the ⁇ -carotene+OLL1224 group, and the ⁇ -carotene+OLL1247 group in comparison with the ⁇ -carotene group.
- Streptococcus thermophilus OLS3290 and Streptococcus thermophilus OLS3078 each were applied to a culture medium containing 10% by mass of defatted powdered milk and 0.1% by weight of casein peptide (manufactured by DOMO, Inc.), and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.6.
- the yogurts thus obtained contained 76.3 ⁇ g/g and 45.8 ⁇ g/g of the polysaccharide, respectively.
- mice 24 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, ⁇ -carotene, a mixture of ⁇ -carotene and the yogurt ( Streptococcus thermophilus OLS3290), and a mixture of ⁇ -carotene and the yogurt ( Streptococcus thermophilus OLS3078) each were administered to the rats of each group.
- 5 mg/kg-body weight of ⁇ -carotene and 11.3 g/kg-body weight of the yogurt were administered.
- Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums.
- the ⁇ -carotene concentrations in the respective serums were measured in accordance with the method described above.
- the rat group to which ⁇ -carotene was administered is called “ ⁇ -carotene group”
- the rat group to which the mixture of ⁇ -carotene and the yogurt ( Streptococcus thermophilus OLS3290) was administered is called “ ⁇ -carotene+OLS3290 group”
- the rat group to which the mixture of ⁇ -carotene and the yogurt ( Streptococcus thermophilus OLS3078) was administered is called “ ⁇ -carotene+OLS3078 group.”
- Results are shown in Table 17.
- the area under the blood concentration-time curve (AUC) was significantly increased in the ⁇ -carotene+OLS3290 group in comparison with the ⁇ -carotene group. This result indicates that the ingestion of the yogurt can promote absorption of ⁇ -carotene.
- a commercially available starter (Caspian sea yogurt, manufactured by Fujicco Co., Ltd.), a combination of Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078, and a combination of Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 each were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.6.
- the yogurts thus obtained contained 15 ⁇ g/g, 54 ⁇ g/g, and 67 ⁇ g/g of the polysaccharide, respectively.
- ⁇ -carotene 5 mg/kg-body weight of ⁇ -carotene and 11.3 g/kg-body weight of the yogurt were administered.
- Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums.
- the ⁇ -carotene concentrations in the respective serums were measured in accordance with the method described above.
- the rat group to which ⁇ -carotene was administered is called “ ⁇ -carotene group”; the rat group to which the mixture of ⁇ -carotene and the yogurt (Caspian sea yogurt) was administered (Comparative Example) is called “ ⁇ -carotene+Caspian sea YG group”; the rat group to which the mixture of ⁇ -carotene and the yogurt ( Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) was administered (Comparative Example) is called “ ⁇ -carotene+OLL1247 ⁇ OLS3078 group”; and the rat group to which the mixture of ⁇ -carotene and the yogurt ( Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290) was administered (Example) is called “ ⁇ -carotene+OLL1251 ⁇ OLS3290 group”.
- Results are shown in Table 4.
- the area under the blood concentration-time curve (AUC) was significantly increased in the ⁇ -carotene+OLL1247 ⁇ OLS3078 group and the ⁇ -carotene+OLL1251 ⁇ OLS3290 group in comparison with the ⁇ -carotene group.
- the rat group to which quercetin was administered is called “quercetin group”
- the rat group to which the mixture of quercetin and the yogurt Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290) was administered (Example) is called “quercetin+OLL1251 ⁇ OLS3290 group”.
- Results are shown in Table 5.
- the area under the blood concentration-time curve (AUC) of the quercetin conjugate in the quercetin+OLL1247 ⁇ OLS3078 group and the quercetin+OLL1251 ⁇ OLS3290 group was significantly increased in comparison with the quercetin group.
- mice 48 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, ⁇ -carotene, a mixture of ⁇ -carotene and the lactic acid bacterium-originated polysaccharide concentrate, a mixture of ⁇ -carotene and cyclodextrin (manufactured by CycloChem Co., Ltd.), a mixture of ⁇ -carotene and starch (originated from rice) (manufactured by Sigma Corp.), a mixture of ⁇ -carotene and pectin (originated from apple) (manufactured by Wako Pure Chemical Industries, Ltd.), and a mixture of ⁇ -carotene and indigestible dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.) each were administered to the rats of each group.
- the rat group to which ⁇ -carotene was administered is called “ ⁇ -carotene group”; the rat group to which the mixture of ⁇ -carotene and the lactic acid bacterium-originated polysaccharide concentrate was administered (Example) is called “ ⁇ -carotene+lactic acid bacterium-originated polysaccharide concentrate group”; the rat group to which the mixture of ⁇ -carotene and cyclodextrin was administered (Comparative Example) is called “ ⁇ -carotene+lactic acid bacterium-originated polysaccharide concentrate group”; the rat group to which the mixture of ⁇ -carotene and starch (originated from rice) was administered (Comparative Example) is called “ ⁇ -carotene+starch (originated from rice) group”; the rat group to which the mixture of ⁇ -carotene and pectin (originated from
- Results are shown in Table 6.
- the area under the serum concentration-time curve (AUC) was significantly increased in the ⁇ -carotene+lactic acid bacterium-originated polysaccharide concentrate group in comparison with the ⁇ -carotene group.
- the AUC in the ⁇ -carotene+cyclodextrin group was significantly decreased in comparison with the ⁇ -carotene group.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 43° C. until its pH reached 4.6.
- Results are shown in Table 7. Amount of change in plasma ⁇ -carotene concentration in the fractionated chylomicron before and after the ingestion of the carrot juice was significantly increased in the carrot juice+yogurt group in comparison with the carrot juice group. This result indicates that in human, fermentation with the lactic acid bacterium promotes absorption of the ⁇ -carotene contained in the carrot juice.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2. In the yogurt thus obtained, 90 ⁇ g/g of the polysaccharide was included.
- the test was carried out to 10 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m 2 or more and 25.0 kg/m 2 or less.
- the subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a vegetable juice (including a commercially available spinach puree, a commercially available tomato puree, a commercially available carrot juice, 5 mg of ⁇ -carotene, 10 mg of ⁇ -carotene, 3 mg of lutein, and 10 mg of lycopene) and 100 g of water, or a beverage containing 100 g of said vegetable juice and 100 g of the yogurt was ingested once into the subjects.
- a vegetable juice including a commercially available spinach puree, a commercially available tomato puree, a commercially available carrot juice, 5 mg of ⁇ -carotene, 10 mg of ⁇ -carotene, 3 mg of lutein, and 10 mg of lycopene
- the beverage that was not ingested in the first ingestion test was ingested once into the subjects.
- the blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- Results are shown in Table 8.
- the areas under the serum concentration-time curve (AUC) of ⁇ -carotene, of ⁇ -carotene, of lutein, and of lycopene were significantly increased in the vegetable juice+yogurt group in comparison with the vegetable juice group. This result indicates that in human the yogurt can promote absorption of the carotenoids included in the vegetable juice.
- the test was carried out to 9 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m 2 or more and 25.0 kg/m 2 or less.
- the subjects were fasted for 16 hours, and then, either a beverage containing 25 g of a carotenoid formulation (10 mg of ⁇ -carotene (manufactured by San-Ei Gen F.F.I., Inc.; New Carotin Base 250) and 10 mg of lycopene (manufactured by Lycored Ltd.; TOMATO-O-Red 2% SG)) and 100 g of water, or a beverage containing 25 g of said carotenoid formulation and 100 g of the yogurt was ingested once into the subjects.
- a carotenoid formulation 10 mg of ⁇ -carotene (manufactured by San-Ei Gen F.F.I., Inc.; New Carotin Base 250) and 10 mg of lycopene (manu
- the beverage that was not ingested in the first ingestion test was ingested once into the subjects.
- the blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- the case that the vegetable juice was ingested (control) is called “carotenoid formulation group”
- the case that the mixture of the carotenoid formulation and the yogurt was ingested (Example) is called “carotenoid formulation+yogurt group”.
- Results are shown in Table 9.
- the areas under the serum concentration-time curve (AUC) of ⁇ -carotene and of lycopene were significantly increased in the carotenoid formulation+yogurt group in comparison with the carotenoid formulation group. This result indicates that in human the yogurt can promote absorption of the carotenoids included in the carotenoid formulation.
- AUC Area Under the blood concentration-time Curve (AUC) of carotenoids originated from carotenoid formulation Carotenoid formulation Carotenoid formulation + group yogurt group ⁇ -Carotene 314 ⁇ 80 812 ⁇ 144* (pmol ⁇ hr/mL) Lycopene 39 ⁇ 44 262 ⁇ 54* (pmol ⁇ hr/mL) Average value ⁇ standard deviation *P ⁇ 0.05: there are significant differences relative to the carotenoid formulation group.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.2.
- the yogurt thus obtained contained 105.8 ⁇ g/g of the polysaccharide.
- 16 rats SD, male, 8 weeks old, Japan SLC, Inc.
- ⁇ -cryptoxanthin and a mixture of ⁇ -cryptoxanthin and the yogurt were administered to the rats of each group.
- 3 mg/kg-body weight of ⁇ -cryptoxanthin and 11.3 g/kg-body weight of the yogurt were administered.
- Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums.
- the rat group to which ⁇ -cryptoxanthin was administered is called “3-cryptoxanthin group”
- the rat group to which the mixture of ⁇ -cryptoxanthin and the yogurt was administered is called “ ⁇ -cryptoxanthin+yogurt group”.
- the 1200 series (manufacture by Agilent Technologies, Inc.) was used.
- TSKgel ODS-80 TsQA (5.0 ⁇ 250 mm) (manufactured by Tosoh Corp.) was used as a column.
- Column temperature was set at 40° C.
- the flow rate was set to 0.3 mL/minute, and the absorbance at the wavelength of 450 nm was measured.
- Results are shown in Table 10 and FIG. 1 .
- the ⁇ -cryptoxanthin concentration in blood at 60 minutes, at 120 minutes, and at 240 minutes after administration was significantly increased in the ⁇ -cryptoxanthin+yogurt group in comparison with the ⁇ -cryptoxanthin group.
- the area under the blood concentration curve (AUC) was significantly increased in the ⁇ -cryptoxanthin+yogurt group in comparison with the ⁇ -cryptoxanthin group.
- 16 rats SD, male, 8 weeks old, Japan SLC, Inc.
- capsanthin and a mixture of capsanthin and the yogurt were administered to the rats of each group.
- 5 mg/kg-body weight of capsanthin and 11.3 g/kg-body weight of the yogurt were administered.
- Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums.
- capsanthin group the rat group to which capsanthin was administered (control)
- capsanthin+yogurt group the rat group to which the mixture of capsanthin and the yogurt was administered
- the 1200 series (manufacture by Agilent Technologies, Inc.) was used.
- TSKgel ODS-80 TsQA (5.0 ⁇ 250 mm) (manufactured by Tosoh Corp.) was used as a column.
- Column temperature was set at 40° C.
- the flow rate was set to 0.3 mL/minute, and the absorbance at the wavelength of 470 nm was measured.
- Results are shown in Table 11 and FIG. 2 .
- the capsanthin concentration in blood at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after administration was significantly increased in the capsanthin+yogurt group in comparison with the capsanthin group.
- the area under the blood concentration curve (AUC) was significantly increased in the capsanthin+yogurt group in comparison with the capsanthin group.
- Capsanthin (pmol ⁇ min/mL) Capsanthin group 3578 ⁇ 232 Capsanthin + yogurt group 5914 ⁇ 715* Average value ⁇ standard deviation *P ⁇ 0.05: there is a significant difference relative to the capsanthin group.
- 16 rats SD, male, 8 weeks old, Japan SLC, Inc.
- hesperidin and a mixture of hesperidin and the yogurt were administered to the rats of each group.
- 162 mg/kg-body weight of hesperidin and 11.3 g/kg-body weight of the yogurt were administered.
- Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, and at 240 minutes after the administration to obtain respective serums.
- hesperidin group the rat group to which hesperidin was administered (control)
- hesperidin+yogurt group the rat group to which the mixture of hesperidin and the yogurt was administered
- a hesperetin conjugate which is a hesperidin metabolite, was measured as follows. 45 uL of a glucoronidase solution (10,000 U/mL; manufactured by Sigma-Aldrich Corp.) dissolved in a 0.1 M sodium acetate buffer solution (pH 5.0), and 5 ⁇ L of a 0.1 M ascorbic acid solution dissolved in a 0.1 M sodium acetate buffer solution (pH 5.0) were added to 50 ⁇ L of the serum; and then, the resulting mixture was warmed at 37° C. for 2 hours.
- a glucoronidase solution 10,000 U/mL; manufactured by Sigma-Aldrich Corp.
- the column was kept with 30% of the B solution for 1 minute, and then, the concentration gradient of B solution was gradually changed up to 45% during a period of 4.5 minutes to elute a target substance. Then, the column was washed with 99% B solution for 2 minutes, and was kept with 30% B solution for 3 minutes. The flow rate was set to 0.3 mL/minute.
- the MS/MS analysis was carried out with an ESI negative mode. The MS/MS analysis was carried out under the following condition: a curtain gas flow rate of 30 psi; a collision gas flow rate of 9 psi; an ion spray voltage of ⁇ 4500 V; a turbo gas temperature of 600° C., and an ion source gas of 70 psi.
- Results are shown in Table 12 and FIG. 3 .
- the hesperetin conjugate concentration in blood at 60 minutes after administration was significantly increased in the hesperidin+yogurt group in comparison with the hesperidin group.
- the area under the blood concentration curve (AUC) was significantly increased in the hesperidin+yogurt group in comparison with the hesperidin group.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2.
- the yogurt thus obtained contained 90 ⁇ g/g of the polysaccharide.
- the test was carried out to 16 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m 2 or more and 25.0 kg/m 2 or less.
- the subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a carrot juice (a commercially available carrot juice containing 6 mg of ⁇ -carotene and 10 mg of ⁇ -carotene) and 100 g of water, or a beverage containing 100 g of said carrot juice and 100 g of the yogurt was ingested once into the subjects.
- the beverage that was not ingested in the first ingestion test was ingested once into the subjects.
- the blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain the respective plasmas.
- Results are shown in Table 14.
- the areas under the plasma blood concentration-time curve (AUC) of ⁇ -carotene and of ⁇ -carotene were significantly increased in the carrot juice+yogurt group in comparison with the carrot juice group. This result indicates that in human the yogurt can promote absorption of the carotenoids contained in the carrot juice.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2.
- the yogurt thus obtained contained 90 ⁇ g/g of the polysaccharide.
- the test was carried out to 15 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m 2 or more and 25.0 kg/m 2 or less.
- the subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a tomato juice (a commercially available tomato juice (containing 10 mg of lycopene)) and 100 g of water, or a beverage containing 100 g of said tomato juice and 100 g of the yogurt was ingested once into the subjects.
- the beverage that was not ingested in the first ingestion test was ingested once into the subjects.
- the blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- tomato juice group the case that the tomato juice was ingested (control) is called “tomato juice group”, and the case that the mixture of the tomato juice and the yogurt was ingested (Example) is called “tomato juice+yogurt group”.
- Results are shown in Table 15.
- the area under the plasma blood concentration-time curve (AUC) of lycopene was significantly increased in the tomato juice+yogurt group in comparison with the tomato juice group. This result indicates that in human the yogurt can promote absorption of the carotenoid contained in the tomato juice.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2.
- the yogurt thus obtained contained 90 ⁇ g/g of the polysaccharide.
- the test was carried out to 16 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m 2 or more and 25.0 kg/m 2 or less.
- the subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a spinach juice (a commercially available spinach juice containing 4.0 mg of lutein and 2.4 mg of ⁇ -carotene) and 100 g of water, or a beverage containing 100 g of said spinach juice and 100 g of the yogurt was ingested once into the subjects.
- a beverage containing 100 g of said spinach juice and 100 g of the yogurt was ingested once into the subjects.
- the blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- Results are shown in Table 16.
- the areas under the plasma blood concentration-time curve (AUC) of lutein and of ⁇ -carotene were significantly increased in the spinach juice+yogurt group in comparison with the spinach juice group. This result indicates that in human the yogurt can promote absorption of the carotenoids contained in the spinach juice.
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2.
- the yogurt thus obtained contained 90 ⁇ g/g the polysaccharide.
- Results are shown in Table 17. Amount of change in ⁇ -cryptoxanthin concentration in the plasma before and after the ingestion of the mandarin orange juice was significantly increased in the mandarin orange juice+yogurt group in comparison with the mandarin orange juice group. This result indicates that in human, fermentation with the lactic acid bacterium promotes absorption of the carotenoid contained in the mandarin orange juice.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dairy Products (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed is a composition for promoting absorption of a poorly water-soluble phytochemical which can significantly improve the intake of a phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood. A polysaccharide-containing lactic acid bacterial product, which is produced by Lactobacillus delbrueckii ssp. bulgaricus OLL1251, can significantly enhance the intake of a phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood. Thus, the composition for promoting absorption of a phytochemical according to the present invention includes, as an active ingredient, the polysaccharide-containing lactic acid bacterial product. Furthermore, the composition for promoting absorption of a phytochemical is useful as a food additive composition. In addition, a food, or a beverage, or a food or beverage composition to which the composition for promoting absorption of a phytochemical is added can obtain an effect of promoting absorption of phytochemical.
Description
- This application is a divisional of U.S. application Ser. No. 17/266,291, filed on Feb. 5, 2021, which is a National Phase under 35 U.S.C. § 371 of International Application No. PCT/JP2019/031112, filed on Aug. 7, 2019, which claims the benefit of priority of Japanese Patent Application No. 2018-149303, filed on Aug. 8, 2018, the entire contents of which are incorporated herein by reference.
- The present invention relates to a composition for promoting absorption of a phytochemical, having an action of promoting absorption of a poorly water-soluble phytochemical into a body.
- Phytochemicals generally mean compounds that are originated from a plant and not essential to keep a usual body function but have a favorable effect on a health condition. For example, isoflavone, which is a polyphenol, is much included in soybeans and has functions of healing a menopause disorder and preventing an osteoporosis; quercetin is much included in an onion and has functions of improving a blood flow and reducing a body fat; β-carotene, which is a terpenoid, is much included in a carrot and a pumpkin, and has functions of maintaining a visual function, an internal mucosa membrane and a skin, and an immune function; and lycopene is much included in a tomato and has functions of decreasing a blood cholesterol and a blood pressure.
- It is known in the art that many phytochemicals are decomposed by being processed and cooked, and eventually disappears, and also known that their migration into a body is sluggish due to many poorly water-soluble components contained therein. Illustrative examples of the popular method for promoting absorption of the poorly water-soluble phytochemical include a method of improving solubility and dispersibility of the phytochemical by its emulsification and formulation, a method of making a particle diameter of the phytochemical smaller, and a method of amorphizing the phytochemical.
- Furthermore, as a method for promoting absorption of the poorly water-soluble phytochemical, for example, JP 2016-216440 A (PTL 1) discloses, as catechins-absorbing promotor, at least one selected from the group consisting of resveratrol, hesperetin, extract from a luo han guo (Siraitia grosvenorii), extract from a red date (Zizyphus jujuba var. inermis), extract from a lime (Citrus aurantiifolia), extract from a lemon (Citrus limon), extract from a pineapple (Ananas comosus), apigenin, glucose, difructose dianhydride III, sucralose, aspartame or a salt thereof, erythritol, inositol, citric acid or a salt thereof, phytic acid or a salt thereof, and gallic acid or a salt thereof.
- JP 2016-93143 A (PTL 2) discloses that when a polyphenol such as catechin having low bioavailability is added to a prescribed blend of a fat and a hydrocarbon, absorption of the polyphenol such as catechin as well as accumulation thereof in a blood plasma can be enhanced.
- JP 2016-506381 A (PTL 3) discloses an enhancer of the bioavailability of catechin, containing cyclodextrin as an active ingredient.
- However, these PTLs do not disclose that a lactic acid bacterial product, which contains a polysaccharide as an active ingredient, has an action of promoting absorption of a phytochemical.
- On the other hand, a combination of a lactic acid bacterium and a phytochemical is disclosed, for example, in JP H08-322464 A (PTL 4). This literature discloses fermented milk obtained by adding about 0.1 to about 2,000 ppm of catechin and tocopherol, respectively, to yogurt containing a lactic acid bacterium and a Bifidobacterium, thereby increasing a productivity of the Bifidobacterium. Furthermore, JP 2015-527076 A (PTL 5) discloses a method for producing a nutrient composition based on a richly-textured milk product, containing a phytochemical. However, none of these PTLs discloses that a lactic acid bacterial product has an action of promoting absorption of a phytochemical.
- A part of the inventors of the present invention previously found that a polysaccharide-containing lactic acid bacterial product significantly improved the intake of a poorly water-soluble phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood; and thus, suggested providing a composition having an action of promoting absorption of the poorly water-soluble phytochemical into a body (PCT/JP2018/010366).
- [PTL 1] JP 2016-216440 A
- [PTL 2] JP 2016-93143 A
- [PTL 3] JP 2016-506381 A
- [PTL 4] JP H08-322464 A
- [PTL 5] JP 2015-527076 A
- The inventors of the present invention have now found that a polysaccharide-containing lactic acid bacterial product produced by a particular strain is capable of significantly promoting the intake of a poorly water-soluble phytochemical into a body, especially a migration speed and/or a migration amount of the phytochemical into a blood.
- Furthermore, in the previously suggested composition for promoting absorption of phytochemical, it has been found that the polysaccharide-containing lactic acid bacterial product is able to be efficiently produced by the combination of particular strains. The present invention was accomplished on the basis of these findings.
- Accordingly, the present invention has an object to provide a composition for promoting absorption of a phytochemical, which has an action of promoting absorption of a poorly water-soluble phytochemical into a body.
- In addition, the present invention has an object to provide a food additive comprising the composition for promoting absorption of a poorly water-soluble phytochemical, as well as a food, a beverage, or a food or beverage composition to which said composition or said food additive is added.
- The composition for promoting absorption of a poorly water-soluble phytochemical according to the present invention comprises a polysaccharide-containing lactic acid bacterial product as an active ingredient, wherein the lactic acid bacterial product is a product produced by Lactobacillus delbrueckii ssp. bulgaricus OLL1251.
- In addition, the food additive, the food or a beverage, or the food or beverage composition according to the present invention comprises the composition for promoting absorption of a poorly water-soluble phytochemical according to the present invention.
- In addition, the present invention relates to a method for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal, comprising the step of administering or ingesting a polysaccharide-containing lactic acid bacterial product to the human or the animal.
- In addition, the present invention relates to a use of a polysaccharide-containing lactic acid bacterial product, for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal.
- In addition, the present invention relates to a use of a polysaccharide-containing lactic acid bacterial product, for preparing the composition for promoting absorption of a poorly water-soluble phytochemical.
-
FIG. 1 A graph illustrating a change of a p-cryptoxanthin concentration in a serum when p-cryptoxanthin alone is administered, or p-cryptoxanthin and a yogurt are administered simultaneously, to a rat. -
FIG. 2 A graph illustrating a change of a p-cryptoxanthin concentration in a serum when capsanthin alone is administered, or capsanthin and a yogurt are administered simultaneously, to a rat. -
FIG. 3 A graph illustrating a change of a hesperetin conjugate concentration in a serum when hesperidin alone is administered, or hesperidin and a yogurt are administered simultaneously, to a rat. - Phytochemicals
- In the present invention, a “phytochemical” means a natural chemical compound present in a plant, a modified body thereof, and a composition containing the compound or the body, wherein the compound, the body, or the composition is administered or is going to be administered as a substance which has a favorable effect on the maintenance or improvement of a health condition but which is not essential to maintain a usual body function. Accordingly, in the present invention, the phytochemical means not only a pure or a somewhat pure compound that is originated from a plant but also a plant-originated composition containing the compound as a main component, or the like, e.g., a fraction of the composition.
- According to a preferred aspect of the present invention, the phytochemical means, for example, a polyphenol, an organic sulfur compound, and a terpenoid.
- In the present invention, illustrative examples of the preferred polyphenol include flavonoids, diketones and tetraterpene. Specifically, illustrative examples of flavonoids include flavones (for example, apigenin and luteolin), isoflavones (for example, genistein and daidzein), flavonols (for example, quercetin, myricetin, and kaempferol), flavanones (for example, hesperetin and naringenin), flavan-3-ols (for example, catechin and epicatechin), and anthocyanins (for example, cyanidin and delphinidin). Curcumin may be mentioned as a specific example of the diketones.
- Illustrative examples of the preferred organic sulfur compound include isothiocyanates (for example, sulforaphane), cysteine sulfoxides (for example, methylcysteine sulfoxide), and sulfines (for example, allicin).
- Tetraterpene may be mentioned as the terpenoid. Specifically, illustrative examples thereof include carotenoids (for example, β-carotene, α-carotene, β-cryptoxanthin, lycopene, lutein, capsanthin, and astaxanthin).
- In the present invention, phytochemicals include analogues of the compounds mentioned above. Illustrative examples of the preferred analogues include: in the case of genistein, its glucoside (genistin) and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of quercetin, its methylated body (isorhamnetin), glucosides (rutin and quercetin glucoside), and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of kaempferol, its glucoside (hesperidin) and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of epicatechin and catechin, their isomers (catechin), polymers (procyanidin B1, procyanidin B2, procyanidin B5, procyanidin C1, and so forth), conjugates (glucuronic acid conjugate and sulfuric acid conjugate), and gallic acid esters (epicatechin gallate and epigallocatechin gallate); in the case of hesperetin, its glucoside (hesperidin) and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of naringenin, its glucosides (kaempferol and astragalin) and conjugates (glucuronic acid conjugate and sulfuric acid conjugate); in the case of β-carotene, its isomers (α-carotene and γ-carotene) and metabolites (retinol palmitate, apo-10-carotenal, and retinol); and in the case of lycopene, its metabolite (apo-10-ricopenal).
- In addition, in the present invention, phytochemicals include extracted and concentrated products that are originated from a plant. Preferred examples thereof include: in the case of genistein, extracted and concentrated products originated from a soy bean, a red bean, a green pea, and a broad bean; in the case of quercetin, extracted and concentrated products originated from an onion and an apple; in the case of kaempferol, extracted and concentrated products originated from a tea and a broccoli; in the case of epicatechin and catechin, extracted and concentrated products originated from a cacao bean and a tea; in the case of hesperetin, extracted and concentrated products originated from a mandarin orange; in the case of naringenin, extracted and concentrated products originated from a grapefruit and an orange; in the case of luteolin, extracted and concentrated products originated from a wild sesame, a perilla, a crown daisy, and a green pepper; in the case of epicatechin, extracted and concentrated products originated from a cacao bean; in the case of β-carotene, extracted and concentrated products originated from a carrot and a spinach; in the case of α-carotene, extracted and concentrated products originated from a carrot; in the case of lycopene, extracted and concentrated products originated from a tomato; in the case of lutein, extracted and concentrated products originated from a yellow carrot, a spinach, and a marigold; and in the case of capsanthin, extracted and concentrated products originated from a bell pepper and a green pepper.
- In the present invention, the phytochemical is poorly water-soluble. According to the preferred aspect of the present invention, a poorly water-soluble phytochemical is the one having the dissolution rate in water of 88% or less, preferably 50% or less, more preferably 20% or less, the most preferably 1% or less. In the present invention, the “dissolution rate” is an index indicating dissolvability of a compound into water, and is also represented by the value, in terms of the percentage (%), obtained by dividing a concentration (w/v) of the compound in a supernatant, which is obtained by shaking the compound in pure water to dissolve the compound therein and by centrifuging the solution, by a concentration (w/v) of the compound in pure water before being dissolved therein. The concentration may be measured by using a spectrophotometer. In the present invention, preferably, a solution prepared by adding 33.3 mg of a phytochemical compound into 10 mL of pure water is used for the measurement of the “dissolution rate”. When a more poorly water-soluble phytochemical is used, the “dissolution rate” may be measured by using a solution that is prepared by adding 3.3 mg of a phytochemical compound into 10 mL of pure water. The temperature condition in the measurement of the “dissolution rate” is set to 21±2° C. Alternatively, poor water solubility of the phytochemical may be expressed, as an index, by “a concentration (w/v) of the compound in a supernatant, which is obtained by shaking the compound in pure water to dissolve the compound therein and by centrifuging the solution”; in this case, the dissolution rate of 88% or less corresponds to 293 mg/100 g or less. In the present invention, it is considered that the phytochemical to be promotingly absorbed is not necessarily in a condition of being dissolved in water. Namely, it is considered that the effect of promoting absorption of the phytochemical exhibited by the present invention can be also obtained when the phytochemical is ingested in a solid condition or in a condition of being suspended in water.
- Composition for Promoting Absorption
- In the present invention, promoting absorption of a phytochemical means that the intake of the phytochemical into a body, in particular, a migration speed and/or a migration amount of the phytochemical into a blood is significantly increased, in comparison with a reference in which the phytochemical is ingested without a polysaccharide-containing lactic acid bacterial product. Specifically, promoting absorption of a phytochemical means that, after the composition is administered, a higher blood concentration is obtained in comparison with the reference, and/or, a larger Area Under the blood concentration-time Curve (AUC) is obtained in comparison with the reference. This allows not only obtaining an effect of ingesting the phytochemical with a smaller quantity or a shorter time, but also reducing costs for a raw material(s). Furthermore, adding the composition for promoting absorption of phytochemical according to the present invention to a food, or a beverage, or a food or beverage composition can enhance an added value of the food or beverage or the like, and thereby also can enhance a commercial value of the same.
- Polysaccharide-Containing Lactic Acid Bacterial Product
- In the present invention, a polysaccharide-containing “lactic acid bacterial product” widely means not only a product fermented with a lactic acid bacterium, but also a composition that is supposed to contain a polysaccharide, as a result of fermentation using a lactic acid bacterium, such as a cultured product with a lactic acid bacterium and a lactic acid bacterial metabolite.
- In the present specification, “polysaccharide” is a saccharide-chained polymer formed of saccharides such as galactose, glucose, rhamnose, mannose, and N-acetyl glucosamine. The polysaccharide may include a neutral polysaccharide and/or an acidic polysaccharide bound to a phosphoric acid group. The molecular weight thereof is usually in the range of 5,000 to 500,000.
- In the present invention, a product produced by Lactobacillus delbrueckii ssp. bulgaricus OLL1251 (which may be hereinafter abbreviated as “Lactobacillus bulgaricus OLL1251”, or “OLL1251”) is used, as the “lactic acid bacterial product”. The “lactic acid bacterial product” produced by OLL1251 has a superior action of promoting absorption of phytochemical in comparison to a product produced by analogous strains.
- According to a preferred aspect of the present invention, it is preferable to use the “lactic acid bacterial product” produced by a combination of OLL1251 and Streptococcus thermophilus OLS3290 (which may be hereinafter abbreviated as “OLS3290”). The combination of OLL1251 and OLS3290 can obtain merits of efficiently producing the “lactic acid bacterial product”, in particular, of obtaining the “lactic acid bacterial product” having a superior action of promoting absorption of the phytochemical in a short fermentation time.
- In accordance with the Budapest Treaty, Lactobacillus delbrueckii ssp. bulgaricus OLL1251 described above is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan) with the deposition date of 25 Apr. 2018 and as the deposition number of NITE BP-02703.
- Also, in accordance with the Budapest Treaty, Streptococcus thermophilus OLS3290 is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center with the deposition date of 19 Jan. 2004 and as the deposition number of FERM BP-19638.
- In this specification, the “product fermented with a lactic acid bacterium” means: a cultured product obtained by fermentation with the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or, as the preferred aspect, with a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290; and a composition including the cultured product; and a composition obtained by processing the composition. Accordingly, the product fermented with a lactic acid bacterium includes a product fermented with Lactobacillus delbrueckii ssp. bulgaricus OLL1251 or with a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290, as well as a product obtained by processing said fermented product. Illustrative examples of the processed product include: a filtrated solution or a supernatant solution of the cultured product that are obtained by sterilizing the cultured product (the product fermented with a lactic acid bacterium) using, for example, filtration, centrifugation, or membrane separation; a concentrated product obtained, using an evaporator or the like, from said filtrated solution or supernatant solution, or product fermented with a lactic acid bacterium, or the like; a pasted product of the fermented product; a diluted product of the fermented product; and a dried product of the fermented product (obtained by, for example, freeze-drying, heat-drying, or decompression-drying). The processing may be carried out by any one of or a combination of a plurality of said processes such as treatments of sterilization (for example, filtration, centrifugation, and membrane separation), precipitation, concentration, pasting, dilution, and drying. Here, illustrative examples of culture media include a defatted milk powder culture medium to which a yeast extract is added and an MRS culture medium.
- According to a preferred aspect of the present invention, the lactic acid bacterial product is especially preferably a fermented milk product, a cultured milk product, or a milk metabolite, which is produced by the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or by a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290. Fermented milk (yogurt) may be mentioned as an example of the fermented milk product, the cultured milk product, or the milk metabolite. In the present invention, the fermented milk (yogurt) may be preferably a supernatant thereof. To the fermented milk, a defatted powder milk and a culture solution such as a decomposed product of whey, as well as a thickener or a gelling agent, such as pectin, guar gum, xanthan gum, carrageenan, processed starch may be added.
- In the present invention, illustrative examples of milk include animal milk such as cow milk and a processed product thereof (for example, defatted milk, whole milk powder, defatted milk powder, condensed milk, casein, whey, fresh cream, compound cream, butter, butter milk powder, and cheese), and plant milk such as soybean milk originated from soybeans. The milk may be sterilized or not be sterilized.
- According to an aspect of the present invention, a so-called raw material admixture for fermented milk may be used as the raw material for fermented milk (yogurt). The raw material admixture for fermented milk is a mixture containing raw material milk and other ingredients. The raw material admixture for fermented milk may be obtained by dissolving, on heating, raw materials that are normally used to produce the fermented milk, such as, raw material milk, water, and other optional ingredients (for example, sugar, carbohydrate, sweetener, acidulant, mineral, vitamin, and fragrance), and thereafter by mixing the raw materials thus dissolved. The raw material milk may include water, raw milk, sterilized milk, defatted milk, powdered whole milk, powdered defatted milk, concentrated whole milk, concentrated defatted milk, butter milk, butter, cream, cheese, and the like. The raw material milk may include whey protein concentrate (WPC), whey protein isolate (WPI), α-lactoalbumin (α-La), β-lactoglobulin (β-Lg), and the like.
- In the present invention, fermented milk (yogurt) may be prepared by the conventional methods in the art. Namely, fermented milk (yogurt) may be prepared via steps: such as a preparation step of a raw material admixture, a (heat-)sterilization step of the raw material admixture, a cooling step of the raw material admixture, an adding step of a starter, a fermentation step, and a cooling step of fermented milk. In these steps, normal conditions used for production of fermented milk (yogurt) may be used as appropriate. preferably, the (heat-)sterilization step of the raw material admixture, the cooling step of the raw material admixture, the adding step of a starter, the fermentation step, and the cooling step of fermented milk are carried out, in this order.
- In the present invention, a culture medium usually used for culturing a lactic acid bacterium in the art may be used, as a culture medium for culturing the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290. Namely, any culture medium may be used so far as the culture medium properly contains a main carbon source as well as a nitrogen source, an inorganic substance and other nutrients. As the carbon source, lactose, glucose, sucrose, fructose, starch hydrolysate, molasses and the like may be used in accordance with assimilation of a strain to be used. As the nitrogen source, nitrogen-containing organic substances such as casein hydrolysate, whey protein hydrolysate, α-lactoalbumin, β-lactoglobulin, glycomacropeptide, and soybean protein hydrolysate. In addition, meat extract, fish extract, yeast extract, or the like may be used, as a growth promoter.
- In the present invention, the lactic acid bacterium, Lactobacillus delbrueckii ssp. bulgaricus OLL1251, or a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 anf Streptococcus thermophilus OLS3290 may be cultured under an anaerobic condition, or under a slightly aerobic condition that is used in liquid static culturing and the like. As the culturing method under an anaerobic condition, a known culturing method such as one under a carbon gas phase may be used, or another method may be used, too. In general, the culturing temperature is preferably in the range of 30° C. or more to 47° C. or less, more preferably in the range of 35° C. or more to 46° C. or less, still more preferably in the range of 37° C. or more to 45° C. or less. The pH of the culture medium during culturing of the lactic acid bacterium is kept preferably in the range of 6 or more to 7 or less; but may be in another range so far as the bacterium can be grown. Usually, the culturing time of the lactic acid bacterium and the like is preferably in the range of 1 hour or more to 48 hours or less, more preferably in the range of 1.5 hours or more to 36 hours or less, still more preferably in the range of 2 hours or more to 24 hours or less.
- According to an aspect of the present invention, fermented milk (yogurt) typically has a milk solids-not-fat concentration of 8% by weight or more, and also has the number of lactic acid bacterium or the number of yeast in the range of 106/mL or more to 1011/mL or less.
- Components of the Composition for Promoting Absorption of Phytochemical, as Well as Form and Optional Ingredient of Said Composition
- In the present invention, as the “composition for promoting absorption”, the “lactic acid bacterial product” may be used as it is in the form of a fermented product, a cultured product, a metabolite, or the like, which is produced by the lactic acid bacterium, Lactobacillus deibrueckii ssp. bulgaricus OLL1251, or a combination of Lactobacillus deibrueckii ssp. bulgaricus OLL1251 and Streptococcus thermophilus OLS3290. It is preferable that the composition for promoting absorption is used in its pharmaceutically formulated form. Therefore, in the present invention, the “composition for promoting absorption” includes, for example, not only a pharmaceutical but also those supplied in a form as they are, or preferably those supplied in a form of formulation orally ingested, i.e., in a form of a so-called supplement. Also, the composition for promoting absorption includes those added, as food additives, to other food, or other food or beverage, thereby providing the food, or the food or beverage with an action of promoting absorption of phytochemical.
- In addition, according to the present invention, a food or a beverage comprising the composition for promoting absorption of phytochemical according to the present invention; the food or the beverage processed; and the food or beverage composition are also encompassed in the present invention.
- In the present invention, a formulation is prepared by a usual method concurrently using an additive acceptable for formularization. The formulation is preferably prepared as an oral formulation. The formulation may be in a form of a solid formulation such as a tablet, a powder, a fine granule, a granule, a capsule, a pill, and a sustained release agent; or in the form of liquid formulation such as a solution, a suspension, and an emulsion. Illustrative examples of the additive acceptable for formularization include an excipient, a stabilizer, a preservative, a wetting agent, an emulsifier, a lubricating agent, a sweetener, a colorant, a fragrance, a buffering agent, an antioxidant, and a pH-adjusting agent. Specifically, illustrative examples of the food additive include seasonings such as a processed seasoning, a flavor seasoning, and a seasoning admixture.
- In the present invention, a food, or a beverage, and a food or beverage composition may be those processed so that a human or an animal can eat or drink them, and may be in orally ingestible form such as a solution, a suspension, an emulsion, a powder, or a molded solid agent, but are not limited to the above. Specifically, illustrated examples of the food or the beverage, and the food or beverage composition include milk products such as a milk beverage (including processed milk), a yogurt, a lactic acid bacterium beverage, a fermented milk, an ice cream, a cream, and a cheese; beverages such as a refreshing beverage, a fruit drink, a vegetable drink, a soybean drink, a coffee drink, a tea drink, a jelly drink, an energy drink, a beauty drink, cocoa, a powdered drink such as smoothie, a powdered sports drink, a nutrient-reinforcing powdered drink, a powdered beauty food, a powdered soup, a source of steamed bread, a concentrated drink, and an alcoholic drink; wheat products such as a bread, a pasta, a noodle, a cake admixture, a frying powder, and a bread powder; sweets such as a chocolate, a gum, a candy, a cookie, a gummi, a snack, a Japanese sweet, jerry, and a dessert cake such as a purine; retort foods such as a curry, a pasta source, a pot-au-feu, a stew, and a Japanese food; fats such as a processed fat, a butter, a margarine, a spread, and mayonnaise; instant foods such as a freeze-dried food; processed agricultural products such as a canned agricultural product, a jam/marmalade, a pickle, a boiled bean, a cereal, and a rice porridge; processed marine products; processed animal products; frozen foods such as a pizza, a rice casserole, a gratin, a side dish, and a fried food; and a fluid food, a semi-fluid food, an animal feed, a tablet, and an oral care cosmetic.
- In the present invention, the food, or a beverage, and the food or beverage composition also include those classified as a functional food, a health and nutrition food, a health food, a food for specified health use, a food with functional claims, a nutrition functional food, a patient food, a formulated milk powder for a baby, a powdered milk for a pregnant or for a lactating mother, a food or beverage with a note of a reduced disease risk, and the like. The note of a reduced disease risk is a note which indicates that the food or a beverage is capable of reducing a disease risk, and also is determined or recognized on the basis of or with reference to the criteria determined by the FAO-WHO Codex Alimentarius Committee (Codex Committee).
- In the present invention, to the food, or a beverage, and the food or beverage composition, an optional ingredient may be added, as needed. The optional ingredient includes those usually blended in a food or a beverage: for example, a sweetener; an acidulant; a juice or an extract of a vegetable, a fruit and a seed; nutritional elements such as a vitamin, a mineral, and an amino acid; a lactic acid bacteria (except for the essential lactic acid bacterium according to the embodiment of the present invention), useful microorganisms such as a Bifidobacterium and a propionic acid bacterium, and their fermented products; functional carbohydrates such as an oligosaccharide; existing functional stuff such as royal jerry, glucosamine, astaxanthin, collagen, and polyphenol; and a flagrance, a pH adjusting agent, an excipient, an acidulant, a colorant, an emulsifier, and a preservative.
- As can be clearly seen in the above description, according to an aspect of the present invention, provided is a use of the polysaccharide-containing lactic acid bacterial product for producing the composition for promoting absorption of a poorly water-soluble phytochemical according to the present invention.
- Method for ingesting the Composition for Promoting Absorption of Phytochemical
- In the present invention, the ingesting amount of the composition for promoting absorption of phytochemical may be determined as appropriate. According to an aspect of the present invention, the ingesting amount of the composition corresponds to the ingesting amount of the polysaccharide in the range of about 200 μg or more/day, preferably in the range of 200 μg/day or more to 60,000 μg/day or less, more preferably in the range of 300 μg/day or more to 45,000 μg/day or less, still more preferably in the range of 400 μg/day or more to 30,000 μg/day or less, the most preferably in the range of 500 μg/day or more to 15,000 μg/day or less. (The expression “mass/day or more” is equivalent to the expression “mass or more/day”, and the expression “mass/day or less” is equivalent to the expression “mass or less/day.”) The ingesting time is not particularly limited. For example, it is preferable that the composition is orally ingested at least one time or more.
- According to another aspect of the present invention, a necessary administering amount obtained from animal testing (for example, mouse testing) may be converted to a necessary administering amount for a human body by using the following formula based on the written material of the Food Safety Commission.
-
[A necessary administering amount to human body (converted value)]=[A necessary administering amount to animal]×[Lower limit of woman's body weight: 40 kg]÷[safety coefficient: 100] - As can be clearly seen in the above description, according to an aspect of the present invention, provided is a method for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal, comprising the steps of administering or ingesting a polysaccharide-containing lactic acid bacterial product to the human or the animal. According to another aspect of the present invention, provided is a use of a polysaccharide-containing lactic acid bacterial product for promoting the intake of a poorly water-soluble phytochemical into a body of a human or an animal.
- In Examples described below, the following strains were used for comparison.
- Lactobacillus delbrueckii ssrp. bulgaricus OLL1247
- In accordance with the Budapest Treaty, this strain is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center (#122, 2-5-8 Kazusakamatari, Kisarazu-shi, Chiba, Japan) with the deposition date of Jun. 3, 2014 and as the deposition number of NITE BP-01814.
- Lactobacillus delbrueckii ssrp. bulgaricus OLL1224
- In accordance with the Budapest Treaty, this strain is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center with the deposition date of Feb. 7, 2009 and as the deposition number of NITE BP-778.
- Streptococcus thermophilus OLS3078
- In accordance with the Budapest Treaty, this strain is internationally deposited to the National Institute of Technology and Evaluation, Patent Microorganisms Depositary Center with the deposition date of 23 Aug. 2013 and as the deposition number of NITE BP-01697.
- In Examples described below, the following measurement methods were commonly used.
- Measurement of Polysaccharide Content in Yogurt
- Content of the polysaccharide in a yogurt was measured in accordance with a phenol sulfuric acid method (Hodge, et al., “Methods in Carbohydrate Chemistry”, Vol. 1, p. 338 (1962)). Specifically, the method is as follows.
- Firstly, 1 g of trichloroacetic acid was added to 10 g of yogurt, and then, they were thoroughly stirred. Next, the trichloroacetic acid-added yogurt was centrifuged under the conditions: at 10,000 rpm for 10 minutes at 4° C., and then, a supernatant thus obtained was transferred to a different tube. Next, ethanol 99.5% the amount of which is twice as much as the supernatant was added to the supernatant. Then, when the ethanol-added supernatant was statically left overnight in a refrigerator, a precipitate was formed in the tube. The precipitate was centrifuged under the condition: at 10,000 rpm for 10 minutes at 4° C., and thereafter, 3 mL of ultrapure water was added to the precipitate thus obtained to prepare a polysaccharide extract solution. Then, 500 μL of a phenol reagent (5% (w/v)) was added to 500 μL of the polysaccharide extract solution, and then, the resulting mixture solution was stirred. Immediately after 2.5 mL of concentrated sulfuric acid was added to the mixture solution, and the resulting mixture solution was stirred for 10 seconds. Then, the mixture solution was statically left for 20 minutes or more at room temperature, the absorbance of the mixture solution at 490 nm was measured with a spectrophotometer. The reference solution was prepared as described below, and the absorbance thereof at 490 nm was measured in a similar manner to the above. In preparation of the reference solution, 500 μL of the phenol reagent (5% (w/v)) was added to 500 μL of a standard glucose solution, followed by stirring the resulting mixture solution. Immediately after 2.5 mL of concentrated sulfuric acid was added to the mixture solution, and the resulting mixture solution was stirred for 10 seconds. Then, the mixture solution was left statically for 20 minutes or more at room temperature.
- Measurement of Quercetin Metabolites
- A quercetin conjugate and an isorhamnetin conjugate, which are quercetin metabolites, were measured as follows. 45 uL of a glucoronidase solution (10,000 U/mL; manufactured by Sigma-Aldrich Corp.) dissolved in a 0.1 M sodium acetate buffer solution (pH 5.0), and 5 μL of a 0.1 M ascorbic acid solution dissolved in a 0.1 M sodium acetate buffer solution (pH 5.0) were added to 50 μL of a serum; and then, the resulting mixture was warmed at 37° C. for 2 hours. Then, 300 μL of methanol was added to the mixture to terminate the enzymatic reaction, and the mixture was centrifuged (at 12,000 rpm for 10 minutes at 4° C.). The supernatant thus obtained was transferred to a different tube, and then, the solvent was removed by centrifugal concentration. The resulting product was dissolved into 300 μL of a 50% acetonitrile solution containing 0.1% formic acid to prepare a sample for HPLC.
- For the HPLC measurement, Nexera XR (manufacture by Shimadzu Corp.) was used. As a MS/MS detector, 4500 QTRAP (manufactured by Sciex Pte. Ltd.) was used. As a column, ACQUITY UPLC HSS T3, 1.8 μm (2.1×50 mm) (manufactured by Waters Corp.) was used. Column temperature was set at 40° C. As for the mobile phase, a 0.1% formic acid solution was prepared as an A solution, and an acetonitrile solution containing 0.1% formic acid was prepared as a B solution. The column was kept with 30% of the B solution for 1 minute, and then, the concentration gradient of B solution was gradually changed up to 45% during a period of 4.5 minutes to elute a target substance. Then, the column was washed with 99% B solution for 2 minutes, and was kept with 30% B solution for 3 minutes. The flow rate was set to 0.3 mL/minute. The MS/MS analysis was carried out with an ESI negative mode. The MS/MS analysis was carried out under the following condition: a curtain gas flow rate of 30 psi; a collision gas flow rate of 9 psi; an ion spray voltage of −4500 V; a turbo gas temperature of 600° C., and an ion source gas of 70 psi.
- Measurement of β-Carotene
- 90 μL of a physiological salt solution and 300 μL of a dichloromethane-methanol solution (dichloromethane:methanol=1:2) were added to 50 μL of a serum. Next, 150 μL of hexane was further added to the resulting solution to extract β-carotene. The upper layer of the solution was transferred to a different tube, and then, the solvent was removed by nitrogen reflux. Then, the resulting product was dissolved into 150 μL of an ethyl acetate-methanol solution (ethyl acetate:methanol=30:70) containing 0.1% ammonium acetate to obtain an sample for HPLC.
- For the HPLC measurement, the 1200 series (manufacture by Agilent Technologies, Inc.) was used. TSKgel ODS-80 TsQA (5.0×250 mm) (manufactured by Tosoh Corp.) was used as a column. Column temperature was set at 40° C. An ethyl acetate-methanol solution (ethyl acetate:methanol=30:70) containing 0.1% ammonium acetate was prepared as a mobile phase. The flow rate was set to 0.3 mL/minute, and the absorbance at the wavelength of 450 nm was measured.
- Evaluation for Dissolvability of Phytochemical
- (1) Experimental Method
- Epicatechin (manufactured by Sigma-Aldrich Corp.), catechin (manufactured by Tokyo Chemical Industry Co., Ltd.), quercetin (manufactured by Wako Pure Chemical Industries, Ltd.), genistein (manufactured by Tokyo Chemical Industry Co., Ltd.), rutin (manufactured by Wako Pure Chemical Industries, Ltd.), α-glucosyl rutin (manufactured by Wako Pure Chemical Industries, Ltd.), hesperidin (manufactured by Wako Pure Chemical Industries, Ltd.), naringin (manufactured by Sigma-Aldrich Corp.), naringenin (manufactured by Sigma-Aldrich Corp.), kaempferol (manufactured by Extra Synthase Inc.), β-carotene (manufactured by Wako Pure Chemical Industries, Ltd.), β-cryptoxanthin (manufactured by Wako Pure Chemical Industries, Ltd.), capsanthin (manufactured by Tokyo Chemical Industry Co., Ltd.), lycopene (manufactured by Wako Pure Chemical Industries, Ltd.), and luteolin (manufactured by Tokyo Chemical Industry Co., Ltd.) were used. In accordance with the administering amount used in Examples, 33.3 mg of each of epicatechin, catechin, quercetin, genistein, naringenin, kaempferol, and luteolin was added to 10 mL of ultrapure water. Furthermore, 10 mL of ultrapure water was added to the glucoside phytochemical such that the amount of aglycone (portion other than carbohydrate obtained by hydrolysis of glucoside) can be equal to 33.3 mg; namely, 67.3 mg of rutin (33.3 mg of quercetin); 89.6 mg of α-glucosyl rutin (33.3 mg of quercetin); 67.3 mg of hesperidin (33.3 mg of hesperetin); or 71.0 mg of naringin (33.3 mg of naringenin). As for the terpenoids, in accordance with the administering amount used in Experiments, 10 mL of ultrapure water was added to 3.3 mg of each of β-carotene and lycopene. The solutions thus prepared were shaken for 3 hours, and then, were centrifuged at 2000×g for 10 minutes. The centrifuged supernatants were filtrated by using a 0.45 μL filter. The absorbance of the centrifuged supernatants were measured by using a spectrophotometer (at 280 nm in the cases of epicatechin, catechin, hesperidin, naringin, naringenin, and luteolin; at 260 nm in the case of genistein; at 360 nm in the cases of quercetin, rutin, α-glucosyl rutin, and kaempferol; at 450 nm in the cases of β-carotene, α-carotene, and β-cryptoxanthin; and at 470 nm in the cases of lycopene and capsanthin). Each compound was dissolved in 80% methanol or methanol to obtain a calibration curve; and then, the concentration of the centrifuged supernatant was obtained. A series of the operations above were carried out under the temperature condition of 21±2° C. The dissolution rate was calculated in accordance with the following formula.
-
Dissolution rate (%)=[(concentration of the centrifuged supernatant after dissolution by shaking (w/v))−(concentration of the solution before dissolution by shaking (w/v)]×100 - (2) Results
- Results are shown in Table 1. Catechin and α-glucosyl rutin had the dissolution rate of 89% or more; and thus, they were water-soluble phytochemicals. On the other hand, epicatechin, genistein, quercetin, rutin, kaempferol, hesperidin, naringin, naringenin, β-carotene, α-carotene, lycopene, luteolin, β-cryptoxanthin, and capsanthin had the dissolution rate of 88% or less; and thus, they were poorly water-soluble. These results indicate that in the poorly water-soluble phytochemicals having the dissolution rate of 88% or less, ingesting the polysaccharide-containing lactic acid bacterial product promotes absorption of the phytochemicals. Here, “concentration (w/v) of the centrifuged supernatant after dissolution by shaking” that is obtained in the measurement of the dissolution rate is called “saturated solubility”, and this is described in Table 1. The value of the glucoside phytochemical is described in terms of that of the corresponding aglycone.
-
TABLE 1 Dissolution rates of phytochemicals Saturated Compound Dissolution solubility Group Compound rate mg/100 g Flavan-3-ol Catechin 97% 323 Epicatechin 86% 287 Isoflavone Genistein 0.2% 0.5 Flavonol Quercetin 0.1% or less 0.1 Rutin 0.3% 1.0 α-Glucosyl rutin 89% 295 Kaempferol 0.1% or less 0.1 Flavanone Hesperidin 0.2% 0.5 Naringin 17% 55 Naringenin 0.3% 1.1 Tetraterpene β-Carotene 0.1% or less 0.1 or less α-Carotene 0.1% or less 0.1 or less β-Cryptoxanthin 0.1% or less 0.1 or less Capsanthin 0.1% or less 0.1 or less Lutein 0.1% or less 0.1 or less Lycopene 0.1% or less 0.1 or less Flavone Luteolin 0.1% or less 0.1 or less - Experiment 1: Promoting Absorption of β-Carotene (Comparison of OLL1251 with Other Strains)
- (1) Preparation of Yogurt
- Lactobacillus delbrueckii ssp. bulgaricus OLL1251, Lactobacillus deibrueckii ssp. bulgaricus OLL1224, and Lactobacillus delbrueckii ssp. bulgaricus OLL1247 each were applied to a culture medium containing 10% by mass of defatted powdered milk and 0.5 mM of sodium formate, and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.6. The yogurts thus obtained contained 136 μg/g, 88 μg/g, and 68 μg/g of the polysaccharide, respectively.
- (2) Experimental Method
- 32 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, β-carotene, a mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1251), a mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1224), and a mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1247) each were administered to the rats of each group. Here, 5 mg/kg-body weight of β-carotene and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums. The β-carotene concentrations in the respective serums were measured in accordance with the method described above.
- Hereinafter, the rat group to which β-carotene was administered (control) is called “β-carotene group”; the rat group to which the mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1251) was administered (Example) is called “β-carotene+OLL1251 group”; the rat group to which the mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1224) was administered (Comparative Example) is called “β-carotene+OLL1224 group”; and the rat group to which the mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1247) was administered (Comparative Example) is called “β-carotene+OLL1247 group.”
- (3) Results
- Results are shown in Table 2. The area under the blood concentration-time curve (AUC) was significantly increased in all of the β-carotene+OLL1251 group, the β-carotene+OLL1224 group, and the β-carotene+OLL1247 group in comparison with the β-carotene group. These results indicate that the ingestion of the yogurt can promote absorption of β-carotene.
-
TABLE 2 Area Under the blood concentration-time Curve (AUC) of β-carotene β-Carotene (ng · min/mL) β-Carotene group 4,502 ± 1,014 β-Carotene + OLL1251 group 31,814 ± 4,293* β-Carotene + OLL1224 group 25,771 ± 5,175* β-Carotene + OLL1247 group 24,375 ± 3,182* Average value ± standard deviation *P < 0.05: there are significant differences relative to the β-carotene group - Experiment 2: Promoting Absorption of β-Carotene (Streptococcus thermophilus OLS3290 alone)
- (1) Preparation of Yogurt
- Streptococcus thermophilus OLS3290 and Streptococcus thermophilus OLS3078 each were applied to a culture medium containing 10% by mass of defatted powdered milk and 0.1% by weight of casein peptide (manufactured by DOMO, Inc.), and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.6. The yogurts thus obtained contained 76.3 μg/g and 45.8 μg/g of the polysaccharide, respectively.
- (2) Experimental Method
- 24 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, β-carotene, a mixture of β-carotene and the yogurt (Streptococcus thermophilus OLS3290), and a mixture of β-carotene and the yogurt (Streptococcus thermophilus OLS3078) each were administered to the rats of each group. Here, 5 mg/kg-body weight of β-carotene and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums. The β-carotene concentrations in the respective serums were measured in accordance with the method described above.
- Hereinafter, the rat group to which β-carotene was administered (control) is called “β-carotene group”; the rat group to which the mixture of β-carotene and the yogurt (Streptococcus thermophilus OLS3290) was administered (Reference Example) is called “β-carotene+OLS3290 group”; and the rat group to which the mixture of β-carotene and the yogurt (Streptococcus thermophilus OLS3078) was administered (Reference Example) is called “β-carotene+OLS3078 group.”
- (3) Results
- Results are shown in Table 17. The area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene+OLS3290 group in comparison with the β-carotene group. This result indicates that the ingestion of the yogurt can promote absorption of β-carotene.
-
TABLE 3 Area Under the blood concentration-time Curve (AUC) of β-carotene β-Carotene (ng · min/mL) β-Carotene group 6,608 ± 892 β-Carotene + OLS3290 group 27,263 ± 4,306* β-Carotene + OLS3078 group 17,416 ± 2,468 Average value ± standard deviation *P < 0.05: there is a significant difference relative to the β-carotene group - Experiment 3: Promoting Absorption of β-Carotene (Combination of Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290)
- (1) Preparation of Yogurt
- A commercially available starter (Caspian sea yogurt, manufactured by Fujicco Co., Ltd.), a combination of Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078, and a combination of Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 each were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.6. The yogurts thus obtained contained 15 μg/g, 54 μg/g, and 67 μg/g of the polysaccharide, respectively.
- (2) Experimental Method
- 32 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, β-carotene, a mixture of β-carotene and the yogurt (Caspian sea yogurt), a mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078), and a mixture of β-carotene with the yogurt (Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290) each were administered to the rats of each group. Here, 5 mg/kg-body weight of β-carotene and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums. The β-carotene concentrations in the respective serums were measured in accordance with the method described above.
- Hereinafter, the rat group to which β-carotene was administered (control) is called “β-carotene group”; the rat group to which the mixture of β-carotene and the yogurt (Caspian sea yogurt) was administered (Comparative Example) is called “β-carotene+Caspian sea YG group”; the rat group to which the mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) was administered (Comparative Example) is called “β-carotene+OLL1247×OLS3078 group”; and the rat group to which the mixture of β-carotene and the yogurt (Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290) was administered (Example) is called “β-carotene+OLL1251×OLS3290 group”.
- (5) Results
- Results are shown in Table 4. The area under the blood concentration-time curve (AUC) was significantly increased in the β-carotene+OLL1247×OLS3078 group and the β-carotene+OLL1251×OLS3290 group in comparison with the β-carotene group. These results indicate that the ingestion of the yogurt can promote absorption of β-carotene.
-
TABLE 4 Area Under the blood concentration-time Curve (AUC) of β-carotene β-Carotene (ng · min/mL) β-Carotene group 5,326 ± 822 β-Carotene + Caspian sea YG group 15,050 ± 2,001 β-Carotene + OLL1247 × OLS3078 group 26,917 ± 4,074* β-Carotene + OLL1251 × OLS3290 group 31,334 ± 6,119* Average value ± standard deviation *P < 0.05: there are significant differences relative to the β-carotene group. - Experiment 4: Promoting Absorption of Quercetin (Combination of Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290)
- (1) Yogurt Used
- The yogurts prepared in Experiment 3 were used.
- (2) Experimental Method
- 24 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, quercetin, and a mixture of quercetin and the yogurt each were administered to the rats of each group. Here, 50 mg/kg-body weight of quercetin and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums. The concentrations of the quercetin conjugate and the isorhamnetin conjugate, which are quercetin metabolites, in the respective serums were measured in accordance with the method described above.
- Hereinafter, the rat group to which quercetin was administered (control) is called “quercetin group”; the rat group to which the mixture of quercetin and the yogurt (Lactobacillus bulgaricus OLL1247 and Streptococcus thermophilus OLS3078) was administered (Comparative Example) is called “quercetin+OLL1247×OLS3078 group”; and the rat group to which the mixture of quercetin and the yogurt (Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290) was administered (Example) is called “quercetin+OLL1251×OLS3290 group”.
- (3) Results
- Results are shown in Table 5. The area under the blood concentration-time curve (AUC) of the quercetin conjugate in the quercetin+OLL1247×OLS3078 group and the quercetin+OLL1251×OLS3290 group was significantly increased in comparison with the quercetin group. These results indicate that the fermentation using the lactic acid bacterium can promote absorption of quercetin.
-
TABLE 5 Area Under the blood concentration-time Curve (AUC) of the quercetin conjugate and the isorhamnetin conjugate Quercetin Isorhamnetin conjugate conjugate (nmol · min/mL) (nmol · min/mL) Quercetin group 745 ± 23 432 ± 13 Quercetin + OLL1247 × 1,097 ± 37* 600 ± 67* OLS3078 group Quercetin + OLL1251 × 1,191 ± 39* 719 ± 41* OLS3290 group Average value ± standard deviation *P < 0.05: there are significant differences relative to the quercetin group. - Experiment 5: Promoting Absorption of β-Carotene (Comparison with Other Absorption Promotors)
- (1) Preparation of Yogurt-Originated Polysaccharide Concentrate
- A part of the yogurt of Experiment 4 (Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290) was taken; and then, to the supernatant thereof was added ethanol the amount of which was three times as much as the supernatant. The resulting mixture was kept in a frozen state, and thereafter, the supernatant of the mixture was centrifuged to obtain a precipitate. This precipitate was freeze-dried to obtain a polysaccharide concentrate. In 11.3 g of the yogurt, 70 mg of the polysaccharide concentrate was included. Hereinafter, the polysaccharide concentrate obtained is called “lactic acid bacterium-originated polysaccharide concentrate”.
- (2) Experimental Method
- 48 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, β-carotene, a mixture of β-carotene and the lactic acid bacterium-originated polysaccharide concentrate, a mixture of β-carotene and cyclodextrin (manufactured by CycloChem Co., Ltd.), a mixture of β-carotene and starch (originated from rice) (manufactured by Sigma Corp.), a mixture of β-carotene and pectin (originated from apple) (manufactured by Wako Pure Chemical Industries, Ltd.), and a mixture of β-carotene and indigestible dextrin (manufactured by Matsutani Chemical Industry Co., Ltd.) each were administered to the rats of each group. Here, 5 mg/kg-body weight of β-carotene and 70 mg/kg-body weight of the polysaccharide were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums.
- For an easy-to-understand explanation, hereinafter, the rat group to which β-carotene was administered (control) is called “β-carotene group”; the rat group to which the mixture of β-carotene and the lactic acid bacterium-originated polysaccharide concentrate was administered (Example) is called “β-carotene+lactic acid bacterium-originated polysaccharide concentrate group”; the rat group to which the mixture of β-carotene and cyclodextrin was administered (Comparative Example) is called “β-carotene+lactic acid bacterium-originated polysaccharide concentrate group”; the rat group to which the mixture of β-carotene and starch (originated from rice) was administered (Comparative Example) is called “β-carotene+starch (originated from rice) group”; the rat group to which the mixture of β-carotene and pectin (originated from apple) was administered (Comparative Example) is called “β-carotene+pectin (originated from apple) group”; and the rat group to which the mixture of β-carotene and indigestible dextrin was administered (Comparative Example) is called “β-carotene+indigestible dextrin group”.
- (5) Results
- Results are shown in Table 6. The area under the serum concentration-time curve (AUC) was significantly increased in the β-carotene+lactic acid bacterium-originated polysaccharide concentrate group in comparison with the β-carotene group. On the other hand, the AUC in the β-carotene+cyclodextrin group was significantly decreased in comparison with the β-carotene group. These results indicate that the ingestion of the polysaccharide originated from the lactic acid bacterium can more highly promote absorption of β-carotene than that of other polysaccharides.
-
TABLE 6 Area Under the blood concentration-time Curve (AUC) of β-carotene β-Carotene (ng · min/mL) β-Carotene group 7,834 ± 1150 β-Carotene + lactic acid bacterium-originated 14,881 ± 2914*# polysaccharide concentrate group β-Carotene + cyclodextrin group 3,483 ± 676* β-Carotene + starch (originated from rice) 5,206 ± 391 group β-Carotene + pectin (originated from apple) 13,545 ± 2205 group β-Carotene + indigestible dextrin group 5,220 ± 804 Average value ± standard deviation *P < 0.05: there is significant differences relative to the β-carotene group. #P < 0.05: there is a significant difference relative to the cyclodextrin group, the starch (originated from rice) group, and the indigestible dextrin group. - Experiment 6: Promoting Absorption of p-Carotene in Human (Addition to Carrot Juice)
- (1) Preparation of Yogurt
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 43° C. until its pH reached 4.6.
- (2) Experimental Method
- 5 human subjects were fasted for 12 hours, and then, 180 g of a commercially available carrot juice (containing 11 mg of β-carotene) was ingested into the subjects. At 4 hours after the ingestion, their serums were taken. After one week of wash-out, a mixture of 180 g of said carrot juice and 100 g of the yogurt was ingested into the subjects, and at 4 hours after the ingestion, their serums were taken. On the serums obtained was stacked a physiological salt solution; and immediately thereafter, the serums were ultracentrifuged (at 155,000×g for 30 minutes) to fractionate a chylomicron.
- (3) Results
- Results are shown in Table 7. Amount of change in plasma β-carotene concentration in the fractionated chylomicron before and after the ingestion of the carrot juice was significantly increased in the carrot juice+yogurt group in comparison with the carrot juice group. This result indicates that in human, fermentation with the lactic acid bacterium promotes absorption of the β-carotene contained in the carrot juice.
-
TABLE 7 Amount of change in plasma β-carotene concentration in the fractionated chylomicron before and after ingesting carrot juice Amount of change in β-carotene before and after ingestion (Δng/mL) Carrot juice group 18.7 ± 2.6 Carrot juice + yogurt group 33.4 ± 7.6* Average value ± standard deviation *P < 0.05: there is a significant difference relative to the carrot juice group. - Experiment 7: Promoting Absorption of Carotenoid in Human (Addition to Vegetable Juice)
- (1) Preparation of Yogurt
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2. In the yogurt thus obtained, 90 μg/g of the polysaccharide was included.
- (2) Experimental Method
- The test was carried out to 10 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m2 or more and 25.0 kg/m2 or less. The subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a vegetable juice (including a commercially available spinach puree, a commercially available tomato puree, a commercially available carrot juice, 5 mg of α-carotene, 10 mg of β-carotene, 3 mg of lutein, and 10 mg of lycopene) and 100 g of water, or a beverage containing 100 g of said vegetable juice and 100 g of the yogurt was ingested once into the subjects. After two weeks of wash-out, the beverage that was not ingested in the first ingestion test was ingested once into the subjects. The blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- For an easy-to-understand explanation, hereinafter, the case that the vegetable juice was ingested (control) is called “vegetable juice group”, and the case that the mixture of the vegetable juice and the yogurt was ingested (Example) is called “vegetable juice+yogurt group”.
- (3) Results
- Results are shown in Table 8. The areas under the serum concentration-time curve (AUC) of α-carotene, of β-carotene, of lutein, and of lycopene were significantly increased in the vegetable juice+yogurt group in comparison with the vegetable juice group. This result indicates that in human the yogurt can promote absorption of the carotenoids included in the vegetable juice.
-
TABLE 8 Area Under the blood concentration-time Curve (AUC) of carotenoids originated from vegetable juice Vegetable juice Vegetable juice + group yogurt group α-Carotene 115 ± 19 152 ± 21* (pmol · hr/mL) β-Carotene 178 ± 32 310 ± 64* (pmol · hr/mL) Rutin 42 ± 21 81 ± 17* (pmol · hr/mL) Lycopene 47 ± 23 147 ± 37* (pmol · hr/mL) Average value ± standard deviation *P < 0.05: there are significant differences relative to the vegetable juice group. - Experiment 8: Promoting Absorption of Carotenoid in Human (Addition to Formulation Including β-Carotene and Lycopene)
- (1) Yogurt Used
- The yogurt prepared in Experiment 7 was used.
- 2) Experimental Method
- The test was carried out to 9 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m2 or more and 25.0 kg/m2 or less. The subjects were fasted for 16 hours, and then, either a beverage containing 25 g of a carotenoid formulation (10 mg of β-carotene (manufactured by San-Ei Gen F.F.I., Inc.; New Carotin Base 250) and 10 mg of lycopene (manufactured by Lycored Ltd.; TOMATO-O-Red 2% SG)) and 100 g of water, or a beverage containing 25 g of said carotenoid formulation and 100 g of the yogurt was ingested once into the subjects. After two weeks of wash-out, the beverage that was not ingested in the first ingestion test was ingested once into the subjects. The blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- For an easy-to-understand explanation, hereinafter, the case that the vegetable juice was ingested (control) is called “carotenoid formulation group”, and the case that the mixture of the carotenoid formulation and the yogurt was ingested (Example) is called “carotenoid formulation+yogurt group”.
- (3) Results
- Results are shown in Table 9. The areas under the serum concentration-time curve (AUC) of β-carotene and of lycopene were significantly increased in the carotenoid formulation+yogurt group in comparison with the carotenoid formulation group. This result indicates that in human the yogurt can promote absorption of the carotenoids included in the carotenoid formulation.
-
TABLE 9 Area Under the blood concentration-time Curve (AUC) of carotenoids originated from carotenoid formulation Carotenoid formulation Carotenoid formulation + group yogurt group β-Carotene 314 ± 80 812 ± 144* (pmol · hr/mL) Lycopene 39 ± 44 262 ± 54* (pmol · hr/mL) Average value ± standard deviation *P < 0.05: there are significant differences relative to the carotenoid formulation group. - Experiment 9: Promoting Absorption of β-Cryptoxanthin
- (1) Yogurt Used
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented on heating at 43° C. until its pH reached 4.2. The yogurt thus obtained contained 105.8 μg/g of the polysaccharide.
- (2) Experimental Method
- 16 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, β-cryptoxanthin and a mixture of β-cryptoxanthin and the yogurt each were administered to the rats of each group. Here, 3 mg/kg-body weight of β-cryptoxanthin and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums. For an easy-to-understand explanation, hereinafter, the rat group to which β-cryptoxanthin was administered (control) is called “3-cryptoxanthin group”, and the rat group to which the mixture of β-cryptoxanthin and the yogurt was administered (Example) is called “β-cryptoxanthin+yogurt group”.
- (3) Measurement of β-Cryptoxanthin
- 90 μL of a physiological salt solution and 300 μL of a dichloromethane-methanol solution (dichloromethane:methanol=1:2) were added to 50 μL of the serum. Next, 150 μL of hexane was further added to the resulting solution to extract β-carotene. The upper layer of the solution was transferred to a different tube, and then, the solvent was removed by nitrogen reflux. Then, the resulting product was dissolved into 150 μL of an ethyl acetate-methanol solution (ethyl acetate:methanol=30:70) containing 0.1% ammonium acetate to obtain an sample for HPLC.
- (4) Condition of HPLC Analysis
- For the HPLC measurement, the 1200 series (manufacture by Agilent Technologies, Inc.) was used. TSKgel ODS-80 TsQA (5.0×250 mm) (manufactured by Tosoh Corp.) was used as a column. Column temperature was set at 40° C. An ethyl acetate-methanol solution (ethyl acetate:methanol=30:70) containing 0.1% ammonium acetate was prepared as a mobile phase. The flow rate was set to 0.3 mL/minute, and the absorbance at the wavelength of 450 nm was measured.
- (5) Results
- Results are shown in Table 10 and
FIG. 1 . The β-cryptoxanthin concentration in blood at 60 minutes, at 120 minutes, and at 240 minutes after administration was significantly increased in the β-cryptoxanthin+yogurt group in comparison with the β-cryptoxanthin group. The area under the blood concentration curve (AUC) was significantly increased in the β-cryptoxanthin+yogurt group in comparison with the β-cryptoxanthin group. These results indicate that ingestion of the yogurt can promote absorption of β-cryptoxanthin. It is noted that the symbol “*” in the figure indicates that there is a significant difference relative to the β-cryptoxanthin group based on P<0.05. -
TABLE 10 β-Cryptoxanthin (pmol · min/mL) β-Cryptoxanthin group 16060 ± 313 β-Cryptoxanthin + yogurt group 25344 ± 1092* Average value ± standard deviation *P < 0.05: there is a significant difference relative to the β-cryptoxanthin group. - Experiment 10: Promoting Absorption of Capsanthin
- (1) Yogurt Used
- The yogurt used in Experiment 9 was used.
- (2) Experimental Method
- 16 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, capsanthin and a mixture of capsanthin and the yogurt each were administered to the rats of each group. Here, 5 mg/kg-body weight of capsanthin and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after the administration to obtain respective serums. For an easy-to-understand explanation, hereinafter, the rat group to which capsanthin was administered (control) is called “capsanthin group”, and the rat group to which the mixture of capsanthin and the yogurt was administered (Example) is called “capsanthin+yogurt group”.
- (3) Measurement of Capsanthin
- 90 μL of a physiological salt solution and 300 μL of a dichloromethane-methanol solution (dichloromethane:methanol=1:2) were added to 50 μL of the serum. Next, 150 μL of hexane was further added to the resulting solution to extract β-carotene. The upper layer of the solution was transferred to a different tube, and then, the solvent was removed by nitrogen reflux. Then, the resulting product was dissolved into 150 μL of an ethyl acetate-methanol solution (ethyl acetate:methanol=30:70) containing 0.1% ammonium acetate to obtain an sample for HPLC.
- (4) Condition of HPLC Analysis
- For the HPLC measurement, the 1200 series (manufacture by Agilent Technologies, Inc.) was used. TSKgel ODS-80 TsQA (5.0×250 mm) (manufactured by Tosoh Corp.) was used as a column. Column temperature was set at 40° C. An ethyl acetate-methanol solution (ethyl acetate:methanol=30:70) containing 0.1% ammonium acetate was prepared as a mobile phase. The flow rate was set to 0.3 mL/minute, and the absorbance at the wavelength of 470 nm was measured.
- (5) Results
- Results are shown in Table 11 and
FIG. 2 . The capsanthin concentration in blood at 60 minutes, at 120 minutes, at 240 minutes, and at 480 minutes after administration was significantly increased in the capsanthin+yogurt group in comparison with the capsanthin group. The area under the blood concentration curve (AUC) was significantly increased in the capsanthin+yogurt group in comparison with the capsanthin group. These results indicate that ingestion of the yogurt can promote absorption of capsanthin. It is noted that the symbol “*” in the figure indicates that there is a significant difference relative to the capsanthin group based on P<0.05. -
TABLE 11 Capsanthin (pmol · min/mL) Capsanthin group 3578 ± 232 Capsanthin + yogurt group 5914 ± 715* Average value ± standard deviation *P < 0.05: there is a significant difference relative to the capsanthin group. - Experiment 11: Promoting Absorption of Hesperidin
- (1) Yogurt Used
- The yogurt used in Experiment 9 was used.
- (2) Experimental Method
- 16 rats (SD, male, 8 weeks old, Japan SLC, Inc.) were acclimated for 7 days, and then, they were divided into the groups each having 8 rats. They were fasted for 16 hours, and then, hesperidin and a mixture of hesperidin and the yogurt each were administered to the rats of each group. Here, 162 mg/kg-body weight of hesperidin and 11.3 g/kg-body weight of the yogurt were administered. Blood sample was taken from a tail vein before the administration, as well as at 60 minutes, at 120 minutes, and at 240 minutes after the administration to obtain respective serums. For an easy-to-understand explanation, hereinafter, the rat group to which hesperidin was administered (control) is called “hesperidin group”, and the rat group to which the mixture of hesperidin and the yogurt was administered (Example) is called “hesperidin+yogurt group”.
- (3) Measurement of Hesperetin Metabolite
- A hesperetin conjugate, which is a hesperidin metabolite, was measured as follows. 45 uL of a glucoronidase solution (10,000 U/mL; manufactured by Sigma-Aldrich Corp.) dissolved in a 0.1 M sodium acetate buffer solution (pH 5.0), and 5 μL of a 0.1 M ascorbic acid solution dissolved in a 0.1 M sodium acetate buffer solution (pH 5.0) were added to 50 μL of the serum; and then, the resulting mixture was warmed at 37° C. for 2 hours. Then, 300 μL of methanol was added to the mixture to terminate the enzymatic reaction, and the mixture was centrifuged (at 12,000 rpm for 10 minutes at 4° C.). The supernatant thus obtained was transferred to a different tube, and then, the solvent was removed by centrifugal concentration. The resulting product was dissolved into 300 μL of a 50% acetonitrile solution containing 0.1% formic acid to prepare a sample for HPLC.
- (4) HPLC Analysis Condition
- For the HPLC measurement. Nexera XR (manufacture by Shimadzu Corp.) was used. As a MS/MS detector, 4500 QTRAP (manufactured by Sciex Pte. Ltd.) was used. As a column, ACQUITY UPLC HSS T3, 1.8 μm (2.1×50 mm) (manufactured by Waters Corp.) was used. Column temperature was set at 40° C. As for the mobile phase, a 0.1% formic acid solution was prepared as an A solution, and an acetonitrile solution containing 0.1% formic acid was prepared as a B solution. The column was kept with 30% of the B solution for 1 minute, and then, the concentration gradient of B solution was gradually changed up to 45% during a period of 4.5 minutes to elute a target substance. Then, the column was washed with 99% B solution for 2 minutes, and was kept with 30% B solution for 3 minutes. The flow rate was set to 0.3 mL/minute. The MS/MS analysis was carried out with an ESI negative mode. The MS/MS analysis was carried out under the following condition: a curtain gas flow rate of 30 psi; a collision gas flow rate of 9 psi; an ion spray voltage of −4500 V; a turbo gas temperature of 600° C., and an ion source gas of 70 psi.
- (5) Results
- Results are shown in Table 12 and
FIG. 3 . The hesperetin conjugate concentration in blood at 60 minutes after administration was significantly increased in the hesperidin+yogurt group in comparison with the hesperidin group. The area under the blood concentration curve (AUC) was significantly increased in the hesperidin+yogurt group in comparison with the hesperidin group. These results indicate that ingestion of the yogurt can promote absorption of the hesperetin conjugate. It is note that the symbol “*” in the figure indicates that there is a significant difference relative to the hesperidin group based on P<0.05. -
TABLE 12 Hesperetin conjugate (pmol · min/mL) Hesperidin group 19699 ± 1368 Hesperidin + yogurt group 25559 ± 1729* Average value ± standard deviation *P < 0.05: there is significant difference relative to the hesperidin group. - Experiment 12: Change of pH During Lactic Acid Bacterial Fermentation
- (1) Experimental Method
- Lactobacillus bulgaricus OLL1251 alone, and a combination of Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 each were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 43° C. to confirm the change of pH.
- (2) Result
- Result is shown in Table 13. The decrease in pH was faster in the fermentation with a combination of Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 in comparison with the fermentation with Lactobacillus bulgaricus OLL1251 alone. This indicates that action of the lactic acid bacterium is active and produces a larger amount of the polysaccharide. From the result, it was confirmed that the fermentation time to produce the polysaccharide can be shortened by combination of the bacteria.
-
TABLE 13 Lactobacillus bulgaricus OLL1251 and Lactobacillus Streptococcus bulgaricus thermophilus OLL1251 OLS3290 Before 6.22 6.22 fermentation 2 Hours 5.86 5.68 3 Hours 5.64 5.24 4 Hours 5.47 4.86 5 Hours 5.32 4.40 6 Hours 5.23 4.18 7 Hours 5.12 4.09 8 Hours 5.11 3.99 - Experiment 13: Promoting Absorption of Carotenoid in Human (Addition to Carrot Juice)
- (1) Preparation of Yogurt
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2. The yogurt thus obtained contained 90 μg/g of the polysaccharide.
- (2) Experimental Method
- The test was carried out to 16 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m2 or more and 25.0 kg/m2 or less. The subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a carrot juice (a commercially available carrot juice containing 6 mg of α-carotene and 10 mg of β-carotene) and 100 g of water, or a beverage containing 100 g of said carrot juice and 100 g of the yogurt was ingested once into the subjects. After two weeks of wash-out, the beverage that was not ingested in the first ingestion test was ingested once into the subjects. The blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain the respective plasmas.
- For an easy-to-understand explanation, hereinafter, the case that the carrot juice was ingested (control) is called “carrot juice group”, and the case that the mixture of the carrot juice and the yogurt was ingested (Example) is called “carrot juice+yogurt group”.
- (3) Results
- Results are shown in Table 14. The areas under the plasma blood concentration-time curve (AUC) of α-carotene and of β-carotene were significantly increased in the carrot juice+yogurt group in comparison with the carrot juice group. This result indicates that in human the yogurt can promote absorption of the carotenoids contained in the carrot juice.
-
TABLE 14 β-Carotene α-Carotene (pmol · hr/mL) (pmol · hr/mL) Carrot juice group 92.5 ± 14.2 70.8 ± 10.2 Carrot juice + yogurt 161.8 ± 18.8* 115.7 ± 12.1* group Average value ± standard deviation *P < 0.05: there is a significant difference relative to the carrot juice group. - Experiment 14: Promoting Absorption of Carotenoid in Human (Addition to Tomato Juice)
- (1) Preparation of Yogurt
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2. The yogurt thus obtained contained 90 μg/g of the polysaccharide.
- (2) Experimental Method
- The test was carried out to 15 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m2 or more and 25.0 kg/m2 or less. The subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a tomato juice (a commercially available tomato juice (containing 10 mg of lycopene)) and 100 g of water, or a beverage containing 100 g of said tomato juice and 100 g of the yogurt was ingested once into the subjects. After two weeks of wash-out, the beverage that was not ingested in the first ingestion test was ingested once into the subjects. The blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- For an easy-to-understand explanation, hereinafter, the case that the tomato juice was ingested (control) is called “tomato juice group”, and the case that the mixture of the tomato juice and the yogurt was ingested (Example) is called “tomato juice+yogurt group”.
- (3) Results
- Results are shown in Table 15. The area under the plasma blood concentration-time curve (AUC) of lycopene was significantly increased in the tomato juice+yogurt group in comparison with the tomato juice group. This result indicates that in human the yogurt can promote absorption of the carotenoid contained in the tomato juice.
-
TABLE 15 Lycopene (pmol · hr/mL) Tomato juice group 2.6 ± 3.6 Tomato juice + yogurt group 16.5 ± 2.9* Average value ± standard deviation *P < 0.05: there is a significant difference relative to the tomato juice group. - Experiment 15: Promoting Absorption of Carotenoid in Human (Addition to Spinach Juice)
- (1) Preparation of Yogurt
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2. The yogurt thus obtained contained 90 μg/g of the polysaccharide.
- (2) Experimental Method
- The test was carried out to 16 male subjects with the age between 20 years old or more and 35 years old or less and with BMI between 18.5 kg/m2 or more and 25.0 kg/m2 or less. The subjects were fasted for 16 hours, and then, either a beverage containing 100 g of a spinach juice (a commercially available spinach juice containing 4.0 mg of lutein and 2.4 mg of β-carotene) and 100 g of water, or a beverage containing 100 g of said spinach juice and 100 g of the yogurt was ingested once into the subjects. After two weeks of wash-out, the beverage that was not ingested in the first ingestion test was ingested once into the subjects. The blood sample was taken before the ingestion of the test food, as well as at 2 hours, at 4 hours, at 6 hours, and at 8 hours after the ingestion to obtain respective plasmas.
- For an easy-to-understand explanation, hereinafter, the case that the spinach juice was ingested (control) is called “spinach juice group”, and the case that the mixture of the spinach juice and the yogurt was ingested (Example) is called “spinach juice+yogurt group”.
- (3) Results
- Results are shown in Table 16. The areas under the plasma blood concentration-time curve (AUC) of lutein and of β-carotene were significantly increased in the spinach juice+yogurt group in comparison with the spinach juice group. This result indicates that in human the yogurt can promote absorption of the carotenoids contained in the spinach juice.
-
TABLE 16 Rutin β-Carotene (pmol · hr/mL) (pmol · hr/mL) Spinach juice group −52.1 ± 14.0 −2.2 ± 3.3 Spinach juice + yogurt group 31.6 ± 7.4* 10.5 ± 5.9* Average value ± standard deviation *P < 0.05: there is a significant difference relative to the spinach juice group. - Experiment 16: Promoting Absorption of Carotenoid in Human (Addition to Mandarin Orange Juice)
- (1) Preparation of Yogurt
- Lactobacillus bulgaricus OLL1251 and Streptococcus thermophilus OLS3290 were applied to a culture medium containing 10% by mass of defatted powdered milk, and then, the culture medium was fermented at 40° C. until its pH reached 4.2. The yogurt thus obtained contained 90 μg/g the polysaccharide.
- 5 male subjects were fasted for 12 hours, and then, 100 g of a commercially available mandarin orange juice (containing 3 mg of β-cryptoxanthin) was ingested into the subjects. At 4 hours after the ingestion, their serum were taken. After one week of wash-out, a mixture of 100 g of said mandarin orange juice and 100 g of the yogurt was ingested into the subjects, and 4 hours after the ingestion, their serums were taken.
- (3) Results
- Results are shown in Table 17. Amount of change in β-cryptoxanthin concentration in the plasma before and after the ingestion of the mandarin orange juice was significantly increased in the mandarin orange juice+yogurt group in comparison with the mandarin orange juice group. This result indicates that in human, fermentation with the lactic acid bacterium promotes absorption of the carotenoid contained in the mandarin orange juice.
-
TABLE 17 β-Cryptoxanthin (Δpmol/mL) Mandarin Orange juice group 5.3 ± 7.5 Mandarin Orange juice + yogurt 20.1 ± 9.6* group Average value ± standard deviation *P < 0.05: there is a significant difference relative to the mandarin orange juice group
Claims (19)
1. A method for preparing a composition, the method comprising:
fermenting a raw material with Lactobacillus delbrueckii ssp. bulgaricus OLL1251 with an accession number NITE BP-02703.
2. The method according to claim 1 , wherein the composition is fermented milk.
3. The method according to claim 2 , wherein the fermented milk is produced by a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 with an accession number NITE BP-02703 and Streptococcus thermophilus OLS3290 with an accession number FERM BP-19638.
4. A method for preparing a composition comprising a polysaccharide-containing lactic acid bacterial product, the method comprising:
fermenting a raw material with Lactobacillus delbrueckii ssp. bulgaricus OLL1251 with an accession number NITE BP-02703.
5. The method according to claim 4 , wherein the composition is fermented milk.
6. The method according to claim 5 , wherein the fermented milk is produced by a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 with an accession number NITE BP-02703 and Streptococcus thermophilus OLS3290 with an accession number FERM BP-19638.
7. A composition, comprising:
a poorly water-soluble phytochemical, and
a polysaccharide-containing lactic acid bacterial product produced by at least a Lactobacillus delbrueckii ssp. bulgaricus OLL1251 with an accession number NITE BP-02703.
8. The composition according to claim 7 , wherein the lactic acid bacterial product is a product produced by a combination of Lactobacillus delbrueckii ssp. bulgaricus OLL1251 with an accession number NITE BP-02703 and Streptococcus thermophilus OLS3290 with an accession number FERM BP-19638.
9. The composition according to claim 7 , wherein the poorly water-soluble phytochemical has the dissolution rate in water of 88% or less.
10. The composition according to claim 7 , wherein the poorly water-soluble phytochemical has the dissolution rate in water of 50% or less.
11. The composition according to claim 7 , wherein the poorly water-soluble phytochemical is selected from the group consisting of a polyphenol, an organic sulfur compound, and a terpenoid.
12. The composition according to claim 11 , wherein the poorly water-soluble phytochemical is a flavonoid.
13. The composition according to claim 12 , wherein the flavonoid is selected from the group consisting of flavone, isoflavone, flavonol, flavanone, flavan-3-ol, anthocyanin, and an analogue thereof.
14. The composition according to claim 13 , wherein the poorly water-soluble phytochemical is selected from the group consisting of flavone, isoflavone, flavonol, flavanone, flavan-3-ol, and an analogue thereof.
15. The composition according to claim 11 , wherein the poorly water-soluble phytochemical is tetraterpene or an analogue thereof.
16. The composition according to claim 7 , wherein the poorly water-soluble phytochemical is selected from the group consisting of quercetin, genistein, epicatechin, luteolin, naringenin, hesperidin, β-carotene, α-carotene, β-cryptoxanthin, capsanthin, lutein, lycopene, and an analogue thereof.
17. The composition according to claim 7 , wherein the composition is fermented milk.
18. A food additive comprising the composition according to claim 7 .
19. A food, or a beverage, or a food or beverage composition comprising the composition according claim 7 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/132,565 US20230241137A1 (en) | 2018-08-08 | 2023-04-10 | Composition for promoting absorption of phytochemicals |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018-149303 | 2018-08-08 | ||
JP2018149303 | 2018-08-08 | ||
PCT/JP2019/031112 WO2020032100A1 (en) | 2018-08-08 | 2019-08-07 | Composition for promoting absorption of phytochemicals |
US202117266291A | 2021-02-05 | 2021-02-05 | |
US18/132,565 US20230241137A1 (en) | 2018-08-08 | 2023-04-10 | Composition for promoting absorption of phytochemicals |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/031112 Division WO2020032100A1 (en) | 2018-08-08 | 2019-08-07 | Composition for promoting absorption of phytochemicals |
US17/266,291 Division US11684644B2 (en) | 2018-08-08 | 2019-08-07 | Composition for promoting absorption of phytochemicals |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230241137A1 true US20230241137A1 (en) | 2023-08-03 |
Family
ID=69415590
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/266,291 Active US11684644B2 (en) | 2018-08-08 | 2019-08-07 | Composition for promoting absorption of phytochemicals |
US18/132,565 Pending US20230241137A1 (en) | 2018-08-08 | 2023-04-10 | Composition for promoting absorption of phytochemicals |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/266,291 Active US11684644B2 (en) | 2018-08-08 | 2019-08-07 | Composition for promoting absorption of phytochemicals |
Country Status (4)
Country | Link |
---|---|
US (2) | US11684644B2 (en) |
JP (1) | JP7385572B2 (en) |
CN (1) | CN112804886B (en) |
WO (1) | WO2020032100A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115267038A (en) * | 2022-09-30 | 2022-11-01 | 中国农业科学院蜜蜂研究所 | Method for identifying rape royal jelly and application |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10645965B2 (en) * | 2013-11-05 | 2020-05-12 | Optibiotix Limited | Dietary composition with probiotics and prebiotics |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH676188A5 (en) * | 1988-10-06 | 1990-12-28 | Nestle Sa | |
JP5766392B2 (en) * | 2008-06-19 | 2015-08-19 | 公立大学法人青森県立保健大学 | Composition for promoting absorption of quercetin and food and drink for promoting absorption of quercetin |
JP6322580B2 (en) * | 2012-12-11 | 2018-05-09 | キッコーマン株式会社 | Soymilk fermented extract and hypocotyl fermented extract |
WO2015068790A1 (en) * | 2013-11-08 | 2015-05-14 | 株式会社明治 | Fermented milk showing suppressed increase in acidity and method for producing same |
JP6653251B2 (en) * | 2014-03-14 | 2020-02-26 | 株式会社明治 | Starter for obtaining fermented milk, low-fat, non-fat ice cream-like food, and method for producing low-fat, non-fat ice-cream-like food |
TW201630596A (en) * | 2015-01-06 | 2016-09-01 | Meiji Co Ltd | Sphingolipid absorption promoter |
WO2017167660A1 (en) * | 2016-03-31 | 2017-10-05 | Chr. Hansen A/S | Use of glucose deficient streptococcus thermophiles strains in a process for producing fermented milk products |
JP6849890B2 (en) * | 2016-07-19 | 2021-03-31 | 株式会社明治 | Composition for preserving deoxyribonucleic acid and its production method, method for preserving deoxyribonucleic acid, lactic acid bacterium product and method for its use |
JP7177039B2 (en) * | 2017-03-16 | 2022-11-22 | 株式会社明治 | Phytochemical absorption enhancer |
-
2019
- 2019-08-07 JP JP2020535833A patent/JP7385572B2/en active Active
- 2019-08-07 WO PCT/JP2019/031112 patent/WO2020032100A1/en active Application Filing
- 2019-08-07 CN CN201980066521.8A patent/CN112804886B/en active Active
- 2019-08-07 US US17/266,291 patent/US11684644B2/en active Active
-
2023
- 2023-04-10 US US18/132,565 patent/US20230241137A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10645965B2 (en) * | 2013-11-05 | 2020-05-12 | Optibiotix Limited | Dietary composition with probiotics and prebiotics |
Also Published As
Publication number | Publication date |
---|---|
US11684644B2 (en) | 2023-06-27 |
JP7385572B2 (en) | 2023-11-22 |
US20210299194A1 (en) | 2021-09-30 |
CN112804886B (en) | 2024-02-06 |
WO2020032100A1 (en) | 2020-02-13 |
CN112804886A (en) | 2021-05-14 |
JPWO2020032100A1 (en) | 2021-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107249356B (en) | Steviol glycoside compounds, compositions for oral ingestion or use, and methods for enhancing the solubility of steviol glycosides | |
CN111031805B (en) | Sweetness and taste improvement of dihydrochalcones on steviol glycosides and mogroside sweeteners | |
CN108289485B (en) | Steviol glycoside blends, compositions, and methods | |
CN108289489B (en) | Steviol glycoside compositions for oral ingestion or use | |
EP2547412B1 (en) | Methods of obtaining natural products from comestible fluids and methods of use | |
US20090143317A1 (en) | Quercetin Glycoside Composition and Method of Preparing the Same | |
CN107072237A (en) | Stevia extract | |
EP2799083B1 (en) | Muscle atrophy inhibitor | |
JP7107855B2 (en) | Steviol glycoside composition or use for oral intake | |
BR112018076303B1 (en) | SWEETENING COMPOSITION, DRINK AND METHOD OF MODIFYING A SENSORY CHARACTERISTICS OF A COMPOSITION | |
JP7177039B2 (en) | Phytochemical absorption enhancer | |
US20230241137A1 (en) | Composition for promoting absorption of phytochemicals | |
KR20200021525A (en) | Intraoral Sweetener Compositions and Methods | |
US8530446B2 (en) | Oral composition containing difructose anhydride | |
CN109259225A (en) | Low-buffer alimentation composition and application thereof | |
WO2006132223A1 (en) | Anti-hypertensive composition | |
CN104023559B (en) | Composition and method of phytonutrients for metabolic programming effects | |
KR102538090B1 (en) | Food composition and health functional food containing Lactobacillus casei IDCC 3451 with proteolytic ability | |
AU2013367872B2 (en) | Igf-1 production-promoting agent | |
WO2024142285A1 (en) | Sleep improving agent | |
KR20220001316A (en) | A composition comprising an extract of Zanthoxylum schinifolium Siebold & Zucc. for treating and preventing hangover | |
KR20220001317A (en) | A composition comprising an extract of Phlomis umbrosa Turcz for treating and preventing hangover | |
JP2021073268A (en) | Muscle-enhancing agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |